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ABSTRACT
Background While it is now apparent clinical sequelae 
(long COVID) may persist after acute COVID-19, their 
nature, frequency and aetiology are poorly characterised. 
This study aims to regularly synthesise evidence on long 
COVID characteristics, to help inform clinical management, 
rehabilitation strategies and interventional studies to 
improve long- term outcomes.
Methods A living systematic review. Medline, CINAHL 
(EBSCO), Global Health (Ovid), WHO Global Research on 
COVID- 19 database, LitCovid and Google Scholar were 
searched till 17 March 2021. Studies including at least 100 
people with confirmed or clinically suspected COVID-19 at 
12 weeks or more post onset were included. Risk of bias 
was assessed using the tool produced by Hoy et al. Results 
were analysed using descriptive statistics and meta- 
analyses to estimate prevalence.
Results A total of 39 studies were included: 32 cohort, 6 
cross- sectional and 1 case–control. Most showed high or 
moderate risk of bias. None were set in low- income countries 
and few included children. Studies reported on 10 951 people 
(48% female) in 12 countries. Most included previously 
hospitalised people (78%, 8520/10 951). The longest mean 
follow- up time was 221.7 (SD: 10.9) days post COVID-19 
onset. Over 60 physical and psychological signs and symptoms 
with wide prevalence were reported, most commonly 
weakness (41%; 95% CI 25% to 59%), general malaise (33%; 
95% CI 15% to 57%), fatigue (31%; 95% CI 24% to 39%), 
concentration impairment (26%; 95% CI 21% to 32%) and 
breathlessness (25%; 95% CI 18% to 34%). 37% (95% CI 
18% to 60%) of patients reported reduced quality of life; 26% 
(10/39) of studies presented evidence of reduced pulmonary 
function.
Conclusion Long COVID is a complex condition with 
prolonged heterogeneous symptoms. The nature of studies 
precludes a precise case definition or risk evaluation. There 
is an urgent need for prospective, robust, standardised, 
controlled studies into aetiology, risk factors and 
biomarkers to characterise long COVID in different at- risk 
populations and settings.
PROSPERO registration number CRD42020211131.
INTRODUCTION
SARS- CoV- 2 first emerged in December 2019 
causing a widespread pandemic. Most people 
experience asymptomatic or mild- to- moderate 
acute COVID- 19 symptoms, while around 
15% of people are estimated to progress to 
more severe disease requiring hospitalisation 
and approximately 5% become critically ill.1
While the acute phase of the disease was 
characterised early, there are still limited 
data on long- term outcomes.2 Symptoms 
of long- lasting COVID- 19 sequelae and 
complications, termed long COVID by 
people living with long COVID,3 have been 
Key questions
What is already known?
 ► A significant number of people continue to describe 
ongoing symptoms long after the acute phase of 
COVID- 19, often referred to as long COVID.
 ► Long COVID is a heterogeneous condition with an 
uncertain prevalence, for which there is currently no 
precise case definition.
What are the new findings?
 ► The breadth of reported symptoms suggests a com-
plex, heterogeneous condition affecting both those 
who were hospitalised and those managed in the 
community.
 ► Our review identifies weakness (41%; 95% CI 25% 
to 59%), general malaise (33%; 95% CI 15% to 
57%), fatigue (31%; 95% CI 24% to 39%), concen-
tration impairment (26%; 95% CI 21% to 32%) and 
breathlessness (25%; 95% CI 18% to 34%) as the 
most common symptoms reported.
What do the new findings imply?
 ► The current evidence base of the clinical spectrum of 
long COVID is limited, based on heterogenous data, 
and vulnerable to biases, hence caution should be used 
when interpreting or generalising the results.
 ► Our review identifies areas where further long COVID 
research is critically needed to help characterise 
long COVID in different populations and define its 
aetiology, risk factors and biomarkers, as well as the 
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reported worldwide. Yet the underlying aetiology behind 
prolonged or fluctuating symptomatology is limited and 
there is no widely accepted uniformed case definition.4 
Instead, long COVID has been defined pragmatically as 
‘not recovering for several weeks or months following the 
start of symptoms’.4 Others have distinguished between 
postacute COVID- 19, referring to symptoms beyond 
3 weeks, and chronic COVID- 19, referring to symptoms 
beyond 12 weeks,5 while the National Institute for Health 
and Care Excellence distinguishes between ongoing 
symptomatic COVID- 19 lasting from 4 to 12 weeks and 
post COVID-19 syndrome continuing for over 12 weeks.6
The number of people living with long COVID is 
unknown. Attempts to quantify the prevalence of long 
COVID use different methods, including national surveys 
and patient- led studies, making it difficult to compare 
across studies. The UK’s Office for National Statistics has 
estimated that on average 1 in 5 people have symptoms 
beyond 5 weeks, while 1 in 10 have symptoms persisting 
over 12 weeks.7 A patient- led survey found that in survival 
analysis, the chance of full recovery by day 50 was smaller 
than 20%8 and a COVID- 19 symptom app study found 
that 13.3% (558/4182) patients had symptoms lasting 28 
days or more, 4.5% (189/4182) patients had symptoms 
for 8 or more weeks and 2.3% (95/4182) patients had 
symptoms lasting over 12 weeks.9
The symptoms of long COVID are equally ill- defined, 
with patients describing it as a fluctuating illness of dispa-
rate symptoms.8 10 Indeed, the National Institute for 
Health Research has suggested that postacute COVID- 19 
may consist of several distinct clinical syndromes 
including: a postintensive care syndrome, chronic fatigue 
syndrome, long- term COVID- 19 syndrome and disease 
from SARS- CoV- 2 inflicted organ damage.11 Addition-
ally, even with an expanding knowledge of risk factors in 
the acute phase, little is currently known on predictive 
factors for developing long COVID.9 Despite suggested 
classifications, there is yet no clear consensus.
Our early understanding of long COVID has been 
accumulated from case reports and cross- sectional 
online survey studies as the pandemic global research 
focus has largely been on studies of hospitalised patients 
during the acute phase. As the pandemic progresses, 
emerging studies have followed up patients to present 
the fluctuating multiorgan sequelae of acute COVID- 19, 
yet evidence is still scarce. There continues to be a call 
to further understand and acknowledge this condition 
by incorporating patient knowledge and experiences, 
together with standardised studies, exploring underlying 
aetiologies behind different syndromes.12 13
Given the enormous number of people worldwide who 
have suffered from COVID- 19, it is essential to establish 
a precise categorisation of long COVID. Such categori-
sation will not only help people better understand their 
symptoms but also direct research into prevention, treat-
ment and support, ultimately allowing us to understand 
and prepare to respond to the long- term consequences 
inflicted by the COVID- 19 pandemic. Our review seeks 
to synthesise and continually update the evidence on the 
character and prevalence of long COVID.
METHODS
Systematic reviews conducted early during the COVID- 19 
pandemic soon became redundant due to the rapidity 
with which new research was released. In recognition of 
this, many reviewers have moved towards the concept of 
a ‘living systematic review’ (LSR), which compared with 
traditional systematic reviews has in- built mechanisms 
for regular update and renewal.14 15 We conducted a 
‘living’ systematic review to provide frequently updated 
evidence on the symptoms and complications of long 
COVID. This review was developed in collaboration with 
infectious disease clinicians, public health professionals, 
information specialists, review methodologists with expe-
rience in clinical epidemic research and members of 
the global Long COVID Support Group, which includes 
people living with long COVID. This is the first version 
of this LSR, which will be updated approximately every 6 
months as new evidence emerges, using the established 
protocol and review platform. The updates will be led by 
the International Severe Acute Respiratory and emerging 
Infection Consortium (ISARIC) systematic review team 
in collaboration with members of Long COVID Support. 
Previous versions will be archived in online supplemental 
materials. The findings will be disseminated via BMJ Global 
Health and on a dedicated webpage with infographics and 
a brief summary for lay people and professionals.
Protocol registration
This report was structured according to the Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses statement guidelines.16 The protocol was regis-
tered with PROSPERO and published in a peer- reviewed 
journal.17
Search strategy
The following databases were searched: Medline and 
CINAHL (EBSCO), Global Health (Ovid), WHO Global 
Research Database on COVID- 19 and LitCovid from 1 
January 2020 to 17 March 2021. Additionally, we searched 
Google Scholar on 17 March 2021, screening the first 
500 titles. A ‘backwards’ snowball search was conducted 
of the references of systematic reviews. Full search terms 
are included in online supplemental file 1. The search 
terms and inclusion criteria have, for this first version, 
been designed to cast a wide net and will be modified in 
line with new evidence, research priorities and clinical 
and policy needs.
Eligibility criteria
Peer- reviewed studies were considered eligible if they 
included at least 100 people with laboratory confirmed 
and/or clinically diagnosed COVID- 19. Without 
a clear, internationally agreed case definition, we 
included studies that reported symptoms or outcomes 
assessed at 12 or more weeks post COVID- 19 onset.6 
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There were no language restrictions. Reviews and 
opinion pieces were excluded. Studies were excluded 
if they included fewer than 100 participants, to avoid 
small study effects,18 or the follow- up was unclear or 
less than 12 weeks post onset.
Screening
Screening was performed independently by two system-
atic reviewers. Any disagreements were resolved via 
consensus or a third reviewer. Non- English articles 
were translated using Google Translate and assessed 
by a systematic reviewer with good knowledge of the 
language. The data were managed using the review soft-
ware Rayyan.19
Data extraction
Data extraction was performed using Microsoft Excel. A 
data extraction template informed by a previous review20 
was reviewed, updated and piloted before being finalised. 
Data extracted included study design, population char-
acteristics, outcomes, prevalence, duration of symptoms 
and risk factors. Data extraction was performed by one 
systematic reviewer and checked by a second reviewer. 
Disagreements were resolved through consensus. To 
avoid duplication of data in future updates and ensure 
robustness, data extraction was not performed for non- 
peer- reviewed preprints.
Risk of bias assessment
The included studies were assessed for risk of bias using 
the tool produced by Hoy et al21 (online supplemental 
file 2). This assessment checklist is a validated tool for 
assessing risk of bias in prevalence studies. The checklist 
has 10 domains for assessing risk of bias, used to calculate 
a cumulative overall risk of bias for the whole study.
Data analysis
We undertook individual descriptive analysis for each 
study. We presented symptom proportions by different 
settings, as presented in the individual studies: hospi-
talised, non- hospitalised or a mix of both populations if 
no subset data were available. Symptoms were broadly 
grouped into physiological clusters through discussion 
with clinicians. Proportion of symptoms and its 95% CIs 
were estimated using the exact method.22 If there were 
two or more studies for each symptom, a meta- analysis 
was performed using a random intercept logistic regres-
sion model with Hartung- Knapp modification due to the 
heterogeneity and skewed sample sizes.23 24 Heterogeneity 
between estimates was assessed using the I2 statistic.25 
Additional subgroup analysis was conducted to explore 
the modification of the following factors on proportion 
of symptoms: hospitalisation, settings, continents and 
follow- up timing. We also conducted meta- regression 
analysis on the percentage of females and intensive care 
unit (ICU) patients where there were more than 10 studies 
for the symptom. Sensitivity analyses were conducted 
to examine the impact of high risk of bias studies and 
statistical methods, Freeman- Tukey double arcsine trans-
formation using inverse variance meta- analysis, on the 
estimates. Funnel plots were plotted using proportion 
of the symptom against the precision and sample sizes22 
where there were more than 10 studies for the symptom 
to explore risk of publication bias. All analysis and data 
presentation were performed using metaprop26 and 
ggplot227 in R (V.4.0.5) via RStudio (V.1.3.1093).28 The 
data are presented using a combination of infographics, 
prepared by a design company (Design Science29) and 
scientific tables to facilitate interpretation by different 
stakeholders, including non- specialists.
Figure 1 Map of study distribution.
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Patient and public involvement
The study team includes members who have been affected 
by long- term COVID- 19 sequalae, including members of 
Long COVID Support,10 a patient support group with 
global reach, with approximately 40 000 members.
They actively contributed to the development of the 
study protocol, to inform the research questions and 
interpretation and presentation of the findings and to 
communicate the results to different audiences. The 
results of this LSR will be disseminated to long COVID 
patient forums for discussion and feedback to inform 
research priorities and updates.
RESULTS
We identified 6459 studies, of which 39 met the inclu-
sion criteria (online supplemental file 3), all of which 
were published in English. Of these, 32 were included in 
the meta- analysis. The remaining studies include single 
symptoms or imaging and diagnostics and are presented 
narratively.
Characteristics of included studies
Most studies were set in Europe (62%, 24/39), followed 
by Asia (23%, 9/39), North America (8%, 3/39) and the 
Middle East 8% (3/39) (figure 1). There was no study 
set in a low- middle income country.30 Most were cohort 
studies (82%, 32/39), followed by cross sectional studies 
(15%, 6/39) and a case–control study (3%, 1/39). These 
studies present data on 10 951 (range: 100–1733) people 
in 12 countries, aged from 9 months to 93 years old and 
48% (5206/10 951) were females.
The map shows the global distribution of the studies 
identified and the shading shows the combined studies 
population size by country.
Most studies included adults, while 10% (4/39) also 
included children.31–34 Only 15% (6/39) of studies 
reported ethnicity of the participants,35–40 but without 
stratification. Table 1 presents the included study 
characteristics.
Most studies (67%, 26/39) were cohorts of hospitalised 
patients post discharge, 10% (4/39) followed up people 
who were not hospitalised, while 23% (9/39) included 
both (hospitalised and non- hospitalised populations). 
Of the inclusions in this review, 78% (8520/10 951) were 
previously hospitalised during the acute COVID- 19 phase 
. Twenty- two studies included people requiring ICU 
admission during the acute phase.31 33–35 37 38 40–55
The longest follow- up period in any study was 
a mean of 221.7 (SD: 10.9) days post onset. Only 
56% (22/39) of studies specified COVID- 19 
severity,31 33–35 37 38 40–55 31% (12/39) treatment 
received during the acute phase36 40 41 45 46 50 53 56–60 and 
62% (24/39) described ventilation support require-
ments.36–42 45 46 48–51 53 54 56 57 60–66 Pre- existing comor-
bidities were reported in the majority of studies (85%, 
33/39), with hypertension and diabetes most commonly 
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Risk of bias
Overall, 12 studies were assessed as high risk of bias, 22 as 
moderate risk of bias and 5 as low risk of bias. Most studies 
had a high risk of bias with regard to the generalisability 
of their results to the wider population with COVID- 19. 
High risk of bias ratings were most common for external 
validity, with item 1 (representation of target population) 
and item 3 (random selection) having the most high 
risk of bias ratings (online supplemental file 2). Further, 
the recruitment process and response rates were often 
not well described and several studies applied different 
data collection methods. Although many studies applied 
validated measurement methods to assess participants, 
most were not designed to detect symptoms arising from 
COVID- 19. Only four studies included a comparative 
control group.35 36 43 44
Symptoms and signs
Patients suffering from long COVID report a wide range 
of new or persistent symptoms, in both the hospital-
ised and non- hospitalised populations. Symptoms were 
broadly organised into physiological ‘clusters’ for the 
purpose of presentation and interpretation of this review 
(figure 2).
The focus of each study included in our analysis 
varied. Some authors focused solely on a specialty, such 
as dentistry, or a specific symptom, such as cognition, 
making comparative analysis difficult. Even among those 
studies which took a broad approach, the prevalence of 
symptoms was diverse. Similarly, the prevalence of the 
more commonly reported symptoms varied markedly.
Within these limitations, we performed a meta- analysis 
of the most commonly reported symptoms and signs of 
long COVID. The most commonly described symptoms 
(with prevalence of 25% or greater) were weakness 
(41%, 95% CI 25.43 to 59.01), general malaise (33%, 
95% CI 14.91 to 57.36), fatigue (31%, 95% CI 23.91 to 
39.03), concentration impairment (26%, 95% CI 20.96 to 
31.73) and breathlessness (25%, 95% CI 17.86 to 33.97). 
Across studies, 37% (95% CI 18.43 to 59.93) of patients 
reported reduced quality of life. Although high I2 values 
(>80%) were observed, they resulted from narrow disper-
sions in the estimates and well- separated estimates and 
CIs between studies (online supplemental file 4). The 
differences between these symptoms and the heteroge-
neity within them are likely to be, to some extent, due 
to other factors (eg, study settings, populations and 
different measurement tools used).
Patients also reported a diverse array of less prevalent 
symptoms and signs, including sweating, chest pain, sore 
throat, anxiety and headaches, among others. The preva-
lence of these symptoms was lower, usually less than 20%. 
Figure 3 presents the range of documented patient symp-
toms and signs, including all the studies.
Figure 4 displays these data by population, including the 
studies that specified hospitalised and non- hospitalised 
cohorts. We also performed subgroup analysis based on 
setting (hospitalised vs non- hospitalised) and follow- up 
time. In several symptoms and signs, the heterogeneity of 
the results was found to be associated with level of hospi-
talisation, hospital settings, location of the studies and 
follow- up timing using subgroup analysis (online supple-
mental files 5- 8). Using meta- regression, the proportion 
of female patients in the studies was positively associated 
with headache and smell and taste disturbance (online 
supplemental file 9), while the proportion of ICU patients 
in the studies was positively associated with muscle pain 
(online supplemental file 10). No major difference was 
found in the sensitivity analyses (online supplemental 
files 11 and 12). Asymmetries found in the funnel plots 
suggest reporting biases and poor methodological quality 
in the included studies (online supplemental file 13).
Imaging and diagnostics
Multiple studies assessed lung sequelae and respiratory 
performance through outpatient visits follow- up (49%, 
19/39).31 37–43 46 48 49 51–54 56 60 61 66 Imaging results were 
reported in 33% (13/39)31 37–39 43 46 48 52–54 56 61 66 of the 
Figure 2 Long COVID signs and symptoms.
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cohort studies, with one including controls43 and one 
with a population including children.31 Authors used 
heterogenous measurement techniques with an observed 
tendency towards novel imaging, including artificial 
intelligence and point‐of‐care ultrasound.43 54 Studies 
found abnormal CT results, including consolidation, 
reticulation, residual ground glass opacity, interstitial 
thickening and fibrotic changes. Some of these studies 
presented comparisons between initial CT findings and 
those at follow- up, showing improvements in pulmo-
nary clinical measures and radiologic resolutions at 
follow- up visits.37 39 46 48 54 One study assessing thrombotic 
complications in COVID- 19 with a minimum of 90- day 
follow- up from critical care admission found low rates 
of hospital- associated venous thromboembolism post 
discharge.66
Pulmonary function tests were reported in 26% 
(10/39) of studies,37 38 41–43 48 49 51 53 61 including spirom-
etry, diffusion capacity, lung volume and exercise tests. 
These studies found evidence of altered pulmonary func-
tion, most frequently significant reduction of carbon 
monoxide transfer factor.
One study assessed kidney function in people with 
COVID- 19- associated acute kidney injury (AKI) compared 
Figure 3 Signs and symptoms in all studies. RoB, risk of bias.
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with people with non- COVID-19- associated AKI, found 
that COVID- 19- related AKI was associated with decreased 
kidney recovery during outpatient follow- up.36
Risk factors
Exploring the literature, we sought to produce a meta- 
analysis of risk factors for long COVID. We found a 
considerable diversity of reported risk factors, including 
age, sex, comorbidities, ethnicity and severity of the acute 
phase.
Several cohorts (64%, 25/39) assessed whether there 
was an association between the severity of initial COVID- 
19, including symptom load, level of hospital care, need for 
mechanical ventilation and the risk of persisting sequelae. 
An association between female gender and long COVID 
risk has also been noted in longitudinal studies (20.5%, 
8/39), as has the association between presence of comor-
bidity,40 55 57 63 68 70 increasing age32 34 50 55 62 63 and minority 
ethnicity,40 67 with long COVID and long COVID risk.
The limitations of the existing evidence base and 
inconsistency of reported findings preclude confident 
conclusions at this time. Instead, we have summarised the 
reported significant associations to date (online supple-
mental file 14) and suggest that these associations be 
explored in prospective controlled trials.
Figure 4 Sign and symptoms in hospitalised and non- hospitalised cohorts.  
Note: The data on sign and symptoms from studies with data on hospitalised or non- hospitalised cohorts, it does not include 
studies that included mixed cohorts without subcategorisation. PTSD, post- traumatic stress disorder.
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DISCUSSION
Our work represents the most comprehensive review of 
evidence regarding long COVID yet produced. Accu-
rate to 17 March 2021, this LSR captures the breadth of 
persistent symptoms reported in 39 studies, including 
over 10 000 people. These data suggest long COVID is a 
syndrome affecting both previously hospitalised and non- 
hospitalised people, characterised by marked fatigue, 
weakness, general malaise, breathlessness and concentra-
tion impairment lasting for a prolonged period of time. 
Besides these common symptoms, there is a diverse array 
of secondary symptoms. The findings in this review show 
symptoms and prevalence aligned to current knowledge 
on long COVID. The Office for National Statistics (ONS) 
Cohort Study, including control participants, reports the 
most common symptoms persisting for 12 or more weeks 
included fatigue (8.3%), headache (7.2%), cough (7%) 
and myalgia (5.6%).7
A deeper understanding of long COVID is currently 
prevented by the limitations of the published literature. 
The studies included in our review were highly heteroge-
neous due to differences in their study designs, settings, 
populations, follow- up time and symptom ascertainment 
methods. In addition, studies used inconsistent termi-
nology describing symptoms and limited details and 
stratification on pre- existing comorbidities, the severity 
of COVID- 19 and treatment methods. This inconsistency 
and limited reporting partly explain the high degree 
of variability observed. The lack of case–control studies 
prevent a direct attribution of symptoms solely to COVID- 
19; larger prospective studies with matched control 
groups are needed. We note that there are large, robust 
prospective cohort studies of hospitalised patients71 and 
non- hospitalised people.72 Simultaneously, qualitative 
studies are ongoing to better explore the long COVID 
patient experience.73
The findings have identified several research gaps and prior-
ities. The majority of long COVID cohorts were conducted 
in Western Europe on patients recently discharged from 
hospital. There is a paucity of evidence on the long- term 
effects of COVID- 19 in low- to- middle income countries and 
in people who were not hospitalised. Similarly, there were 
no studies identified focusing on children, despite evidence 
showing that children and young people are also affected by 
long COVID.74 Additionally, no study stratified by ethnicity, 
an important risk factor for the acute phase.
Our review also highlights a need for standardised and 
validated COVID- 19 research tools to harmonise data collec-
tion, improve quality and reduce reporting variability. For 
instance, fatigue is one of the most commonly reported 
symptoms of long COVID. However, the symptom alone is 
not clearly defined and it is open to different interpretations, 
hence it requires a validated tool such as the Visual Analogue 
Scale, graded fatigue scale for robust, objective and compar-
ative analysis. ISARIC has developed open access research 
tools available to sites globally to facilitate standardisation 
of data collection, analysis and interpretation for adults and 
children of an age.75 We support the broader use of this tool 
as well as initiatives to standardise outcome measures for 
long COVID.
Similarly, our study highlights the need for further 
research to refine the many circulating interim case defi-
nitions and precisely characterise long COVID, including 
the potential impacts of variants of concern and vaccina-
tion on long COVID.
As this is an LSR, emerging themes from this first 
version will inform future updates. The LSR will be 
updated periodically, as new research is published inter-
nationally, in order to provide relevant up to date infor-
mation for clinicians, patients, researchers, policy- makers 
and health- service commissioners. Version changes will 
be identified and previous reports will be archived.
CONCLUSION
This LSR summarises published evidence on the spec-
trum of long- term COVID- 19- associated symptoms and 
sequelae (as of 17 March 2021). It is clear that long 
COVID affects different populations, with a wide range 
of symptomatology. Our findings suggest this multiorgan 
syndrome is characterised by fatigue, weakness, malaise, 
breathlessness and concentration impairment, among 
other less frequent symptoms. Currently, the strength 
of the available evidence is limited and prone to bias. 
The long- term effects of COVID- 19, in both hospital-
ised and non- hospitalised individuals, including chil-
dren and at- risk populations, should be a priority for 
future research using standardised and controlled study 
designs. Robust research is needed to characterise and 
define long COVID and identify risk factors and under-
lying aetiology, in order to inform prevention, rehabilita-
tion, clinical and public health management to improve 
recovery and long- term COVID- 19 outcomes. This LSR 
will be updated approximately every 6 months as new 
evidence emerges for up to 2 years.
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Supplement 1: Search strategy summary 
Database Strategy Results 
(16/3/2021) 
Medline (EBSCOhost) (COVID-19 OR covid OR SARS-CoV-2. ab)  
AND  
(symptom* OR "clinical features" OR signs OR characteristic* OR sequela* OR complication*.ab)  
AND 
("long-term Covid" OR long-term OR consequence* OR "long-term impact" OR "long-term effect" OR "post-acute" 
OR long-tail OR persist* OR "chronic-COVID" OR "long-COVID" OR post-discharge OR postdischarge OR "prolonged 
symptom" OR "long-haul" .ab) 
Limits: 2020- 
1952 
CINAHL (EBSCOhost) (COVID-19 OR covid OR SARS-CoV-2. ab)  
AND  
(symptom* OR "clinical features" OR signs OR characteristic* OR sequela* OR complication*.ab)  
AND  
("long-term Covid" OR long-term OR consequence* OR "long-term impact" OR "long-term effect" OR "post-acute" 
OR long-tail OR persist* OR "chronic-COVID" OR "long-COVID" OR post-discharge OR postdischarge OR "prolonged 
symptom" OR "long-haul" .ab) 
Limits: 2020- 
384 
Global Health (COVID-19 or covid or SARS-CoV-2)  
AND  
(symptom* or "clinical features" or signs or characteristic* or sequelae or complication*)  
AND  
((("long-term Covid" or long-term) adj2 consequence*) or "long-term impact" or "long-term effect" or "post-acute" 
or long-tail or persist* or "chronic-COVID" or "long-COVID" or post-discharge or postdischarge or "prolonged 




(WHO COVID, ELSEVIER and 
Lanzhou University/CNKI) 
tw:((ab:(covid-19 OR covid OR sars-cov-2)) AND (ab:(symptom OR "clinical features" OR signs OR characteristic OR 
sequela OR complication)) AND (ab:("long-term Covid" OR "long-term consequence" OR "long-term impact" OR 
"long-term effect" OR "post-acute" OR long-tail OR persist* OR "chronic-COVID" OR "long-COVID" OR post-discharge 
OR postdischarge OR "prolonged symptom" OR "long-haul"))) AND db:("COVIDWHO" OR "ELSEVIER" OR 
"CNKI_Lanzhou") 
195 
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Lit Covid (“persistent symptoms” OR “after covid-19 infection").ti,ab,kw 
OR 
 ((“outcomes “ OR “characteristics” OR “features” OR “symptoms” OR “inflammation” OR “function” OR 
“complications” OR “syndrome” OR “manifestation”) ADJ10 (“long-haul” OR “recovery” OR “recovered” OR 
“recovering” OR “survivors” OR “post-discharge” OR “postdischarge” OR “discharge” OR “persisting” OR “prolonged” 
OR “long-term” OR “after admission” OR “post-COVID-19” OR “post-COVID”)).ti,ab. 
OR 
 ((“outcomes “ OR “characteristics” OR “features” OR “symptoms” OR “inflammation” OR “function” OR 
“complications” OR “syndrome” OR “manifestation”) ADJ/10 (“after admission” OR “after hospital” OR “after 
hospitalisation" OR “after hospitalization" OR “after COVID-19” OR “after SARS-CoV-2")).ti,ab. 
1432 
Google Scholar post COVID after discharge persistent symptom 1000 
Ovid Embase (top-up) [17 Mar 
2021] 
See Appendix 1 
Limit: 2020- 
483 
Ovid Medline (top-up) [17 Mar 
2021] 




[19 Mar 2021] 
(excluded: PREPRINT-BIORXVI,  
PREPRINT-MEDRXVI,   PREPRINT-
other preprint, ITCRP) 
See Appendix 3 340 
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Database(s): Embase 1974 to 2021 March 17 
# Searches Results 
1 (long* adj3 (covid* or ncov* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).mp. 462 
2 (persist* adj3 (covid* or ncov* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).mp. 265 
3 (chronic adj3 (covid* or ncov* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).mp. 191 
4 ((long term or long-term or longterm) adj3 effect* adj3 (covid* or ncov* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).mp. 59 
5 (sequela* adj3 (covid* or ncov* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).mp. 150 
6 ((post acute or post-acute or postacute) adj3 (covid* or ncov* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).mp. 38 
7 ((longhaul* or long haul* or long-haul*) adj3 (covid* or ncov* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).mp. 18 
8 ((post-covid* or postcovid*) adj2 (syndrome or condition)).mp. 32 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 1123 
10 symptom/ 151132 
11 symptom assessment/ 8515 
12 exp complication/ 1237024 
13 (symptom* or "clinical feature*" or signs or characteristic* or sequela* or complication*).mp. 6906139 
14 exp physical disease by body function/ 9306422 
15 10 or 11 or 12 or 13 or 14 13028765 
16 9 and 15 748 
17 limit 16 to yr="2020" 483 
 
Appendix 2 
Database(s): Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations and Daily 1946 to March 17, 2021 
# Searches Results 
1 (long* adj3 (covid* or ncov* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).mp. 507 
2 (persist* adj3 (covid* or ncov* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).mp. 273 
3 (chronic adj3 (covid* or ncov* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).mp. 173 
4 ((long term or long-term or longterm) adj3 effect* adj3 (covid* or ncov* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).mp. 62 
5 (sequela* adj3 (covid* or ncov* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).mp. 159 
6 ((post acute or post-acute or postacute) adj3 (covid* or ncov* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).mp. 66 
7 ((longhaul* or long haul* or long-haul*) adj3 (covid* or ncov* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).mp. 25 
8 ((post-covid* or postcovid*) adj2 (syndrome or condition)).mp. 36 
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9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 1179 
10 exp "signs and symptoms"/ 2127623 
11 (symptom* or "clinical feature*" or signs or characteristic* or sequela* or complication*).tw. 3644236 
12 10 or 11 5362470 
13 9 and 12 591 
14 limit 13 to yr="2020" 336 
 
Appendix 3 
There are only three strings of syntax:  
1. keywords and phrases associated with “long COVID” 
2. keywords and phrases associated with “hospitalisation” and “quarantine” 
3. keywords and phrases associated with “symptoms” and “complications” 
The combinations of 1 AND 3 and 2 AND 3 were used to search in the combinations of title, abstract and TW (title + abstract + subjects) in the database. These consist of 18 searches as 
follows: 
# Syntax Hits 
1 (ti:(post-COVID* OR post-nCov* OR "post novel coronavirus" OR "post novel betacoronavirus" OR "post SARS-nCoV-2" OR "post SARS-CoV-2" OR postCOVID* OR "post nCov*" 
OR "long* COVID*" OR "long* nCov*" OR "long* novel coronavirus" OR "long* novel betacoronavirus" OR "long* SARS-nCoV-2" OR "long* SARS-CoV-2" OR "long-term COVID*" 
OR "long-term nCov*" OR "long-term novel coronavirus" OR "long-term novel betacoronavirus" OR "long-term SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "long-term 
COVID*" OR "longterm COVID*" OR "post acute COVID*" OR "postacute COVID*" OR "longhaul* COVID*" OR "long haul* COVID*" OR "long-haul* COVID*" OR "chronic* 
COVID*" OR "prolonged* COVID*" OR "presist* COVID*" OR "long-term nCov*" OR "longterm nCov*" OR "post acute nCov*" OR "postacute nCov*" OR "longhaul* nCov*" OR 
"long haul* nCov*" OR "long-haul* nCov*" OR "chronic* nCov*" OR "prolonged* nCov*" OR "presist* nCov*" OR "long-term novel coronavirus" OR "longterm novel 
coronavirus" OR "post acute novel coronavirus" OR "postacute novel coronavirus" OR "longhaul* novel coronavirus" OR "long haul* novel coronavirus" OR "long-haul* novel 
coronavirus" OR "chronic* novel coronavirus" OR "prolonged* novel coronavirus" OR "presist* novel coronavirus" OR "long-term novel betacoronavirus" OR "longterm novel 
betacoronavirus" OR "post acute novel betacoronavirus" OR "postacute novel betacoronavirus" OR "longhaul* novel betacoronavirus" OR "long haul* novel betacoronavirus" 
OR "long-haul* novel betacoronavirus" OR "chronic* novel betacoronavirus" OR "prolonged* novel betacoronavirus" OR "presist* novel betacoronavirus" OR "long-term SARS-
nCoV-2" OR "longterm SARS-nCoV-2" OR "post acute SARS-nCoV-2" OR "postacute SARS-nCoV-2" OR "longhaul* SARS-nCoV-2" OR "long haul* SARS-nCoV-2" OR "long-haul* 
SARS-nCoV-2" OR "chronic* SARS-nCoV-2" OR "prolonged* SARS-nCoV-2" OR "presist* SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "longterm SARS-CoV-2" OR "post acute 
SARS-CoV-2" OR "postacute SARS-CoV-2" OR "longhaul* SARS-CoV-2" OR "long haul* SARS-CoV-2" OR "long-haul* SARS-CoV-2" OR "chronic* SARS-CoV-2" OR "prolonged* 
SARS-CoV-2" OR "presist* SARS-CoV-2") AND ti:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR 
dysfunction OR illness* OR impair* OR inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
135 
2 (ti:("after admission" OR "after discharg*" OR "after hospital*" OR "after isolat*" OR "after quarantine" OR "after self isolat*" OR "after self-isolat*" OR "after self-quarantine" 
OR "post admission" OR "post discharg*" OR "post hospital*" OR "post isolat*" OR "post quarantine" OR "post self isolat*" OR "post self-isolat*" OR "post self-quarantine") 
AND ti:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR dysfunction OR illness* OR impair* OR 
inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
11 
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3 (ti:(post-COVID* OR post-nCov* OR "post novel coronavirus" OR "post novel betacoronavirus" OR "post SARS-nCoV-2" OR "post SARS-CoV-2" OR postCOVID* OR "post nCov*" 
OR "long* COVID*" OR "long* nCov*" OR "long* novel coronavirus" OR "long* novel betacoronavirus" OR "long* SARS-nCoV-2" OR "long* SARS-CoV-2" OR "long-term COVID*" 
OR "long-term nCov*" OR "long-term novel coronavirus" OR "long-term novel betacoronavirus" OR "long-term SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "long-term 
COVID*" OR "longterm COVID*" OR "post acute COVID*" OR "postacute COVID*" OR "longhaul* COVID*" OR "long haul* COVID*" OR "long-haul* COVID*" OR "chronic* 
COVID*" OR "prolonged* COVID*" OR "presist* COVID*" OR "long-term nCov*" OR "longterm nCov*" OR "post acute nCov*" OR "postacute nCov*" OR "longhaul* nCov*" OR 
"long haul* nCov*" OR "long-haul* nCov*" OR "chronic* nCov*" OR "prolonged* nCov*" OR "presist* nCov*" OR "long-term novel coronavirus" OR "longterm novel 
coronavirus" OR "post acute novel coronavirus" OR "postacute novel coronavirus" OR "longhaul* novel coronavirus" OR "long haul* novel coronavirus" OR "long-haul* novel 
coronavirus" OR "chronic* novel coronavirus" OR "prolonged* novel coronavirus" OR "presist* novel coronavirus" OR "long-term novel betacoronavirus" OR "longterm novel 
betacoronavirus" OR "post acute novel betacoronavirus" OR "postacute novel betacoronavirus" OR "longhaul* novel betacoronavirus" OR "long haul* novel betacoronavirus" 
OR "long-haul* novel betacoronavirus" OR "chronic* novel betacoronavirus" OR "prolonged* novel betacoronavirus" OR "presist* novel betacoronavirus" OR "long-term SARS-
nCoV-2" OR "longterm SARS-nCoV-2" OR "post acute SARS-nCoV-2" OR "postacute SARS-nCoV-2" OR "longhaul* SARS-nCoV-2" OR "long haul* SARS-nCoV-2" OR "long-haul* 
SARS-nCoV-2" OR "chronic* SARS-nCoV-2" OR "prolonged* SARS-nCoV-2" OR "presist* SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "longterm SARS-CoV-2" OR "post acute 
SARS-CoV-2" OR "postacute SARS-CoV-2" OR "longhaul* SARS-CoV-2" OR "long haul* SARS-CoV-2" OR "long-haul* SARS-CoV-2" OR "chronic* SARS-CoV-2" OR "prolonged* 
SARS-CoV-2" OR "presist* SARS-CoV-2") AND ab:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR 
dysfunction OR illness* OR impair* OR inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
352 
4 (ti:("after admission" OR "after discharg*" OR "after hospital*" OR "after isolat*" OR "after quarantine" OR "after self isolat*" OR "after self-isolat*" OR "after self-quarantine" 
OR "post admission" OR "post discharg*" OR "post hospital*" OR "post isolat*" OR "post quarantine" OR "post self isolat*" OR "post self-isolat*" OR "post self-quarantine") 
AND ab:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR dysfunction OR illness* OR impair* OR 
inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
35 
5 (ti:(post-COVID* OR post-nCov* OR "post novel coronavirus" OR "post novel betacoronavirus" OR "post SARS-nCoV-2" OR "post SARS-CoV-2" OR postCOVID* OR "post nCov*" 
OR "long* COVID*" OR "long* nCov*" OR "long* novel coronavirus" OR "long* novel betacoronavirus" OR "long* SARS-nCoV-2" OR "long* SARS-CoV-2" OR "long-term COVID*" 
OR "long-term nCov*" OR "long-term novel coronavirus" OR "long-term novel betacoronavirus" OR "long-term SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "long-term 
COVID*" OR "longterm COVID*" OR "post acute COVID*" OR "postacute COVID*" OR "longhaul* COVID*" OR "long haul* COVID*" OR "long-haul* COVID*" OR "chronic* 
COVID*" OR "prolonged* COVID*" OR "presist* COVID*" OR "long-term nCov*" OR "longterm nCov*" OR "post acute nCov*" OR "postacute nCov*" OR "longhaul* nCov*" OR 
"long haul* nCov*" OR "long-haul* nCov*" OR "chronic* nCov*" OR "prolonged* nCov*" OR "presist* nCov*" OR "long-term novel coronavirus" OR "longterm novel 
coronavirus" OR "post acute novel coronavirus" OR "postacute novel coronavirus" OR "longhaul* novel coronavirus" OR "long haul* novel coronavirus" OR "long-haul* novel 
coronavirus" OR "chronic* novel coronavirus" OR "prolonged* novel coronavirus" OR "presist* novel coronavirus" OR "long-term novel betacoronavirus" OR "longterm novel 
betacoronavirus" OR "post acute novel betacoronavirus" OR "postacute novel betacoronavirus" OR "longhaul* novel betacoronavirus" OR "long haul* novel betacoronavirus" 
OR "long-haul* novel betacoronavirus" OR "chronic* novel betacoronavirus" OR "prolonged* novel betacoronavirus" OR "presist* novel betacoronavirus" OR "long-term SARS-
nCoV-2" OR "longterm SARS-nCoV-2" OR "post acute SARS-nCoV-2" OR "postacute SARS-nCoV-2" OR "longhaul* SARS-nCoV-2" OR "long haul* SARS-nCoV-2" OR "long-haul* 
SARS-nCoV-2" OR "chronic* SARS-nCoV-2" OR "prolonged* SARS-nCoV-2" OR "presist* SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "longterm SARS-CoV-2" OR "post acute 
SARS-CoV-2" OR "postacute SARS-CoV-2" OR "longhaul* SARS-CoV-2" OR "long haul* SARS-CoV-2" OR "long-haul* SARS-CoV-2" OR "chronic* SARS-CoV-2" OR "prolonged* 
SARS-CoV-2" OR "presist* SARS-CoV-2") AND tw:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR 
dysfunction OR illness* OR impair* OR inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
508 
6 (ti:("after admission" OR "after discharg*" OR "after hospital*" OR "after isolat*" OR "after quarantine" OR "after self isolat*" OR "after self-isolat*" OR "after self-quarantine" 
OR "post admission" OR "post discharg*" OR "post hospital*" OR "post isolat*" OR "post quarantine" OR "post self isolat*" OR "post self-isolat*" OR "post self-quarantine") 
AND tw:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR dysfunction OR illness* OR impair* OR 
inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
38 
7 (ab:(post-COVID* OR post-nCov* OR "post novel coronavirus" OR "post novel betacoronavirus" OR "post SARS-nCoV-2" OR "post SARS-CoV-2" OR postCOVID* OR "post nCov*" 
OR "long* COVID*" OR "long* nCov*" OR "long* novel coronavirus" OR "long* novel betacoronavirus" OR "long* SARS-nCoV-2" OR "long* SARS-CoV-2" OR "long-term COVID*" 
159 
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OR "long-term nCov*" OR "long-term novel coronavirus" OR "long-term novel betacoronavirus" OR "long-term SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "long-term 
COVID*" OR "longterm COVID*" OR "post acute COVID*" OR "postacute COVID*" OR "longhaul* COVID*" OR "long haul* COVID*" OR "long-haul* COVID*" OR "chronic* 
COVID*" OR "prolonged* COVID*" OR "presist* COVID*" OR "long-term nCov*" OR "longterm nCov*" OR "post acute nCov*" OR "postacute nCov*" OR "longhaul* nCov*" OR 
"long haul* nCov*" OR "long-haul* nCov*" OR "chronic* nCov*" OR "prolonged* nCov*" OR "presist* nCov*" OR "long-term novel coronavirus" OR "longterm novel 
coronavirus" OR "post acute novel coronavirus" OR "postacute novel coronavirus" OR "longhaul* novel coronavirus" OR "long haul* novel coronavirus" OR "long-haul* novel 
coronavirus" OR "chronic* novel coronavirus" OR "prolonged* novel coronavirus" OR "presist* novel coronavirus" OR "long-term novel betacoronavirus" OR "longterm novel 
betacoronavirus" OR "post acute novel betacoronavirus" OR "postacute novel betacoronavirus" OR "longhaul* novel betacoronavirus" OR "long haul* novel betacoronavirus" 
OR "long-haul* novel betacoronavirus" OR "chronic* novel betacoronavirus" OR "prolonged* novel betacoronavirus" OR "presist* novel betacoronavirus" OR "long-term SARS-
nCoV-2" OR "longterm SARS-nCoV-2" OR "post acute SARS-nCoV-2" OR "postacute SARS-nCoV-2" OR "longhaul* SARS-nCoV-2" OR "long haul* SARS-nCoV-2" OR "long-haul* 
SARS-nCoV-2" OR "chronic* SARS-nCoV-2" OR "prolonged* SARS-nCoV-2" OR "presist* SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "longterm SARS-CoV-2" OR "post acute 
SARS-CoV-2" OR "postacute SARS-CoV-2" OR "longhaul* SARS-CoV-2" OR "long haul* SARS-CoV-2" OR "long-haul* SARS-CoV-2" OR "chronic* SARS-CoV-2" OR "prolonged* 
SARS-CoV-2" OR "presist* SARS-CoV-2") AND ti:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR 
dysfunction OR illness* OR impair* OR inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
8 (ab:("after admission" OR "after discharg*" OR "after hospital*" OR "after isolat*" OR "after quarantine" OR "after self isolat*" OR "after self-isolat*" OR "after self-quarantine" 
OR "post admission" OR "post discharg*" OR "post hospital*" OR "post isolat*" OR "post quarantine" OR "post self isolat*" OR "post self-isolat*" OR "post self-quarantine") 
AND ti:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR dysfunction OR illness* OR impair* OR 
inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
202 
9 (ab:(post-COVID* OR post-nCov* OR "post novel coronavirus" OR "post novel betacoronavirus" OR "post SARS-nCoV-2" OR "post SARS-CoV-2" OR postCOVID* OR "post nCov*" 
OR "long* COVID*" OR "long* nCov*" OR "long* novel coronavirus" OR "long* novel betacoronavirus" OR "long* SARS-nCoV-2" OR "long* SARS-CoV-2" OR "long-term COVID*" 
OR "long-term nCov*" OR "long-term novel coronavirus" OR "long-term novel betacoronavirus" OR "long-term SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "long-term 
COVID*" OR "longterm COVID*" OR "post acute COVID*" OR "postacute COVID*" OR "longhaul* COVID*" OR "long haul* COVID*" OR "long-haul* COVID*" OR "chronic* 
COVID*" OR "prolonged* COVID*" OR "presist* COVID*" OR "long-term nCov*" OR "longterm nCov*" OR "post acute nCov*" OR "postacute nCov*" OR "longhaul* nCov*" OR 
"long haul* nCov*" OR "long-haul* nCov*" OR "chronic* nCov*" OR "prolonged* nCov*" OR "presist* nCov*" OR "long-term novel coronavirus" OR "longterm novel 
coronavirus" OR "post acute novel coronavirus" OR "postacute novel coronavirus" OR "longhaul* novel coronavirus" OR "long haul* novel coronavirus" OR "long-haul* novel 
coronavirus" OR "chronic* novel coronavirus" OR "prolonged* novel coronavirus" OR "presist* novel coronavirus" OR "long-term novel betacoronavirus" OR "longterm novel 
betacoronavirus" OR "post acute novel betacoronavirus" OR "postacute novel betacoronavirus" OR "longhaul* novel betacoronavirus" OR "long haul* novel betacoronavirus" 
OR "long-haul* novel betacoronavirus" OR "chronic* novel betacoronavirus" OR "prolonged* novel betacoronavirus" OR "presist* novel betacoronavirus" OR "long-term SARS-
nCoV-2" OR "longterm SARS-nCoV-2" OR "post acute SARS-nCoV-2" OR "postacute SARS-nCoV-2" OR "longhaul* SARS-nCoV-2" OR "long haul* SARS-nCoV-2" OR "long-haul* 
SARS-nCoV-2" OR "chronic* SARS-nCoV-2" OR "prolonged* SARS-nCoV-2" OR "presist* SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "longterm SARS-CoV-2" OR "post acute 
SARS-CoV-2" OR "postacute SARS-CoV-2" OR "longhaul* SARS-CoV-2" OR "long haul* SARS-CoV-2" OR "long-haul* SARS-CoV-2" OR "chronic* SARS-CoV-2" OR "prolonged* 
SARS-CoV-2" OR "presist* SARS-CoV-2") AND ab:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR 
dysfunction OR illness* OR impair* OR inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
800 
10 (ab:("after admission" OR "after discharg*" OR "after hospital*" OR "after isolat*" OR "after quarantine" OR "after self isolat*" OR "after self-isolat*" OR "after self-quarantine" 
OR "post admission" OR "post discharg*" OR "post hospital*" OR "post isolat*" OR "post quarantine" OR "post self isolat*" OR "post self-isolat*" OR "post self-quarantine") 
AND ab:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR dysfunction OR illness* OR impair* OR 
inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
680 
11 (ab:(post-COVID* OR post-nCov* OR "post novel coronavirus" OR "post novel betacoronavirus" OR "post SARS-nCoV-2" OR "post SARS-CoV-2" OR postCOVID* OR "post nCov*" 
OR "long* COVID*" OR "long* nCov*" OR "long* novel coronavirus" OR "long* novel betacoronavirus" OR "long* SARS-nCoV-2" OR "long* SARS-CoV-2" OR "long-term COVID*" 
OR "long-term nCov*" OR "long-term novel coronavirus" OR "long-term novel betacoronavirus" OR "long-term SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "long-term 
COVID*" OR "longterm COVID*" OR "post acute COVID*" OR "postacute COVID*" OR "longhaul* COVID*" OR "long haul* COVID*" OR "long-haul* COVID*" OR "chronic* 
830 
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COVID*" OR "prolonged* COVID*" OR "presist* COVID*" OR "long-term nCov*" OR "longterm nCov*" OR "post acute nCov*" OR "postacute nCov*" OR "longhaul* nCov*" OR 
"long haul* nCov*" OR "long-haul* nCov*" OR "chronic* nCov*" OR "prolonged* nCov*" OR "presist* nCov*" OR "long-term novel coronavirus" OR "longterm novel 
coronavirus" OR "post acute novel coronavirus" OR "postacute novel coronavirus" OR "longhaul* novel coronavirus" OR "long haul* novel coronavirus" OR "long-haul* novel 
coronavirus" OR "chronic* novel coronavirus" OR "prolonged* novel coronavirus" OR "presist* novel coronavirus" OR "long-term novel betacoronavirus" OR "longterm novel 
betacoronavirus" OR "post acute novel betacoronavirus" OR "postacute novel betacoronavirus" OR "longhaul* novel betacoronavirus" OR "long haul* novel betacoronavirus" 
OR "long-haul* novel betacoronavirus" OR "chronic* novel betacoronavirus" OR "prolonged* novel betacoronavirus" OR "presist* novel betacoronavirus" OR "long-term SARS-
nCoV-2" OR "longterm SARS-nCoV-2" OR "post acute SARS-nCoV-2" OR "postacute SARS-nCoV-2" OR "longhaul* SARS-nCoV-2" OR "long haul* SARS-nCoV-2" OR "long-haul* 
SARS-nCoV-2" OR "chronic* SARS-nCoV-2" OR "prolonged* SARS-nCoV-2" OR "presist* SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "longterm SARS-CoV-2" OR "post acute 
SARS-CoV-2" OR "postacute SARS-CoV-2" OR "longhaul* SARS-CoV-2" OR "long haul* SARS-CoV-2" OR "long-haul* SARS-CoV-2" OR "chronic* SARS-CoV-2" OR "prolonged* 
SARS-CoV-2" OR "presist* SARS-CoV-2") AND tw:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR 
dysfunction OR illness* OR impair* OR inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
12 (ab:("after admission" OR "after discharg*" OR "after hospital*" OR "after isolat*" OR "after quarantine" OR "after self isolat*" OR "after self-isolat*" OR "after self-quarantine" 
OR "post admission" OR "post discharg*" OR "post hospital*" OR "post isolat*" OR "post quarantine" OR "post self isolat*" OR "post self-isolat*" OR "post self-quarantine") 
AND tw:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR dysfunction OR illness* OR impair* OR 
inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
681 
13 (tw:(post-COVID* OR post-nCov* OR "post novel coronavirus" OR "post novel betacoronavirus" OR "post SARS-nCoV-2" OR "post SARS-CoV-2" OR postCOVID* OR "post nCov*" 
OR "long* COVID*" OR "long* nCov*" OR "long* novel coronavirus" OR "long* novel betacoronavirus" OR "long* SARS-nCoV-2" OR "long* SARS-CoV-2" OR "long-term COVID*" 
OR "long-term nCov*" OR "long-term novel coronavirus" OR "long-term novel betacoronavirus" OR "long-term SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "long-term 
COVID*" OR "longterm COVID*" OR "post acute COVID*" OR "postacute COVID*" OR "longhaul* COVID*" OR "long haul* COVID*" OR "long-haul* COVID*" OR "chronic* 
COVID*" OR "prolonged* COVID*" OR "presist* COVID*" OR "long-term nCov*" OR "longterm nCov*" OR "post acute nCov*" OR "postacute nCov*" OR "longhaul* nCov*" OR 
"long haul* nCov*" OR "long-haul* nCov*" OR "chronic* nCov*" OR "prolonged* nCov*" OR "presist* nCov*" OR "long-term novel coronavirus" OR "longterm novel 
coronavirus" OR "post acute novel coronavirus" OR "postacute novel coronavirus" OR "longhaul* novel coronavirus" OR "long haul* novel coronavirus" OR "long-haul* novel 
coronavirus" OR "chronic* novel coronavirus" OR "prolonged* novel coronavirus" OR "presist* novel coronavirus" OR "long-term novel betacoronavirus" OR "longterm novel 
betacoronavirus" OR "post acute novel betacoronavirus" OR "postacute novel betacoronavirus" OR "longhaul* novel betacoronavirus" OR "long haul* novel betacoronavirus" 
OR "long-haul* novel betacoronavirus" OR "chronic* novel betacoronavirus" OR "prolonged* novel betacoronavirus" OR "presist* novel betacoronavirus" OR "long-term SARS-
nCoV-2" OR "longterm SARS-nCoV-2" OR "post acute SARS-nCoV-2" OR "postacute SARS-nCoV-2" OR "longhaul* SARS-nCoV-2" OR "long haul* SARS-nCoV-2" OR "long-haul* 
SARS-nCoV-2" OR "chronic* SARS-nCoV-2" OR "prolonged* SARS-nCoV-2" OR "presist* SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "longterm SARS-CoV-2" OR "post acute 
SARS-CoV-2" OR "postacute SARS-CoV-2" OR "longhaul* SARS-CoV-2" OR "long haul* SARS-CoV-2" OR "long-haul* SARS-CoV-2" OR "chronic* SARS-CoV-2" OR "prolonged* 
SARS-CoV-2" OR "presist* SARS-CoV-2") AND ti:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR 
dysfunction OR illness* OR impair* OR inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
167 
14 (tw:("after admission" OR "after discharg*" OR "after hospital*" OR "after isolat*" OR "after quarantine" OR "after self isolat*" OR "after self-isolat*" OR "after self-quarantine" 
OR "post admission" OR "post discharg*" OR "post hospital*" OR "post isolat*" OR "post quarantine" OR "post self isolat*" OR "post self-isolat*" OR "post self-quarantine") 
AND ti:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR dysfunction OR illness* OR impair* OR 
inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
93 
 
15 (tw:(post-COVID* OR post-nCov* OR "post novel coronavirus" OR "post novel betacoronavirus" OR "post SARS-nCoV-2" OR "post SARS-CoV-2" OR postCOVID* OR "post nCov*" 
OR "long* COVID*" OR "long* nCov*" OR "long* novel coronavirus" OR "long* novel betacoronavirus" OR "long* SARS-nCoV-2" OR "long* SARS-CoV-2" OR "long-term COVID*" 
OR "long-term nCov*" OR "long-term novel coronavirus" OR "long-term novel betacoronavirus" OR "long-term SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "long-term 
COVID*" OR "longterm COVID*" OR "post acute COVID*" OR "postacute COVID*" OR "longhaul* COVID*" OR "long haul* COVID*" OR "long-haul* COVID*" OR "chronic* 
COVID*" OR "prolonged* COVID*" OR "presist* COVID*" OR "long-term nCov*" OR "longterm nCov*" OR "post acute nCov*" OR "postacute nCov*" OR "longhaul* nCov*" OR 
"long haul* nCov*" OR "long-haul* nCov*" OR "chronic* nCov*" OR "prolonged* nCov*" OR "presist* nCov*" OR "long-term novel coronavirus" OR "longterm novel 
752 
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coronavirus" OR "post acute novel coronavirus" OR "postacute novel coronavirus" OR "longhaul* novel coronavirus" OR "long haul* novel coronavirus" OR "long-haul* novel 
coronavirus" OR "chronic* novel coronavirus" OR "prolonged* novel coronavirus" OR "presist* novel coronavirus" OR "long-term novel betacoronavirus" OR "longterm novel 
betacoronavirus" OR "post acute novel betacoronavirus" OR "postacute novel betacoronavirus" OR "longhaul* novel betacoronavirus" OR "long haul* novel betacoronavirus" 
OR "long-haul* novel betacoronavirus" OR "chronic* novel betacoronavirus" OR "prolonged* novel betacoronavirus" OR "presist* novel betacoronavirus" OR "long-term SARS-
nCoV-2" OR "longterm SARS-nCoV-2" OR "post acute SARS-nCoV-2" OR "postacute SARS-nCoV-2" OR "longhaul* SARS-nCoV-2" OR "long haul* SARS-nCoV-2" OR "long-haul* 
SARS-nCoV-2" OR "chronic* SARS-nCoV-2" OR "prolonged* SARS-nCoV-2" OR "presist* SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "longterm SARS-CoV-2" OR "post acute 
SARS-CoV-2" OR "postacute SARS-CoV-2" OR "longhaul* SARS-CoV-2" OR "long haul* SARS-CoV-2" OR "long-haul* SARS-CoV-2" OR "chronic* SARS-CoV-2" OR "prolonged* 
SARS-CoV-2" OR "presist* SARS-CoV-2") AND ab:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR 
dysfunction OR illness* OR impair* OR inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
16 (tw:("after admission" OR "after discharg*" OR "after hospital*" OR "after isolat*" OR "after quarantine" OR "after self isolat*" OR "after self-isolat*" OR "after self-quarantine" 
OR "post admission" OR "post discharg*" OR "post hospital*" OR "post isolat*" OR "post quarantine" OR "post self isolat*" OR "post self-isolat*" OR "post self-quarantine") 
AND ab:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR dysfunction OR illness* OR impair* OR 
inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
339 
 
17 (tw:(post-COVID* OR post-nCov* OR "post novel coronavirus" OR "post novel betacoronavirus" OR "post SARS-nCoV-2" OR "post SARS-CoV-2" OR postCOVID* OR "post nCov*" 
OR "long* COVID*" OR "long* nCov*" OR "long* novel coronavirus" OR "long* novel betacoronavirus" OR "long* SARS-nCoV-2" OR "long* SARS-CoV-2" OR "long-term COVID*" 
OR "long-term nCov*" OR "long-term novel coronavirus" OR "long-term novel betacoronavirus" OR "long-term SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "long-term 
COVID*" OR "longterm COVID*" OR "post acute COVID*" OR "postacute COVID*" OR "longhaul* COVID*" OR "long haul* COVID*" OR "long-haul* COVID*" OR "chronic* 
COVID*" OR "prolonged* COVID*" OR "presist* COVID*" OR "long-term nCov*" OR "longterm nCov*" OR "post acute nCov*" OR "postacute nCov*" OR "longhaul* nCov*" OR 
"long haul* nCov*" OR "long-haul* nCov*" OR "chronic* nCov*" OR "prolonged* nCov*" OR "presist* nCov*" OR "long-term novel coronavirus" OR "longterm novel 
coronavirus" OR "post acute novel coronavirus" OR "postacute novel coronavirus" OR "longhaul* novel coronavirus" OR "long haul* novel coronavirus" OR "long-haul* novel 
coronavirus" OR "chronic* novel coronavirus" OR "prolonged* novel coronavirus" OR "presist* novel coronavirus" OR "long-term novel betacoronavirus" OR "longterm novel 
betacoronavirus" OR "post acute novel betacoronavirus" OR "postacute novel betacoronavirus" OR "longhaul* novel betacoronavirus" OR "long haul* novel betacoronavirus" 
OR "long-haul* novel betacoronavirus" OR "chronic* novel betacoronavirus" OR "prolonged* novel betacoronavirus" OR "presist* novel betacoronavirus" OR "long-term SARS-
nCoV-2" OR "longterm SARS-nCoV-2" OR "post acute SARS-nCoV-2" OR "postacute SARS-nCoV-2" OR "longhaul* SARS-nCoV-2" OR "long haul* SARS-nCoV-2" OR "long-haul* 
SARS-nCoV-2" OR "chronic* SARS-nCoV-2" OR "prolonged* SARS-nCoV-2" OR "presist* SARS-nCoV-2" OR "long-term SARS-CoV-2" OR "longterm SARS-CoV-2" OR "post acute 
SARS-CoV-2" OR "postacute SARS-CoV-2" OR "longhaul* SARS-CoV-2" OR "long haul* SARS-CoV-2" OR "long-haul* SARS-CoV-2" OR "chronic* SARS-CoV-2" OR "prolonged* 
SARS-CoV-2" OR "presist* SARS-CoV-2") AND tw:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR 
dysfunction OR illness* OR impair* OR inflammation OR manifestation OR outcome* OR prevalence OR problem* OR sequela* OR sign* OR symptom* OR syndrome)) 
906 
18 (tw:("after admission" OR "after discharg*" OR "after hospital*" OR "after isolat*" OR "after quarantine" OR "after self isolat*" OR "after self-isolat*" OR "after self-quarantine" 
OR "post admission" OR "post discharg*" OR "post hospital*" OR "post isolat*" OR "post quarantine" OR "post self isolat*" OR "post self-isolat*" OR "post self-quarantine") 
AND tw:("clinical feature*" OR abnormal* OR characteristic* OR complication* OR condition* OR convalescence OR disorder* OR dysfunction OR illness* OR impair* OR 
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Supplement 2: Risk of bias assessment
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health
 doi: 10.1136/bmjgh-2021-005427:e005427. 6 2021;BMJ Global Health, et al. Michelen M
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health
 doi: 10.1136/bmjgh-2021-005427:e005427. 6 2021;BMJ Global Health, et al. Michelen M
12 
 
Supplement 4: Individual forest plots in main results 
Figure 1. Cardiopulmonary 
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Figure 2.Cardiopulmonary (page 2) 
 
  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health
 doi: 10.1136/bmjgh-2021-005427:e005427. 6 2021;BMJ Global Health, et al. Michelen M
14 
 




BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health
 doi: 10.1136/bmjgh-2021-005427:e005427. 6 2021;BMJ Global Health, et al. Michelen M
15 
 
Figure 4. Musculoskeletal 
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Figure 5. Neurocognitive 
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Figure 6. Neurological and neuromuscular 
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Figure 7.Neurological and neuromuscular (page 2) 
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Figure 8. Neurological and neuromuscular (page 3) 
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Figure 9. Other 
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Figure 10. Psychological and social 
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Figure 11. Systemic 
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Figure 12. Upper respiratory 
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Supplement 5: Subgroup analysis: hospitalisation 




Hospitalised n = 14  765/3148 28.68 (18.48 to 41.64) 96.19 
<0.001 Mixed n = 3  381/1291 32.57 (14.26 to 58.38) 96.38 
Non-hospitalised n = 4  151/1084 13.72 (8.51 to 21.37) 72.13 
Chest pain 
Mixed n = 2   69/1146  6.18 (0.01 to 97.66) 96.65 
0.071 Hospitalised n = 9  225/3636  5.92 (2.45 to 13.63) 92.86 
Non-hospitalised n = 1   14/ 96 14.58 (8.83 to 23.13) NA 
Cough 
Mixed n = 3   54/1281  4.91 (0.25 to 51.82) 96.03 
0.265 Hospitalised n = 11  299/2769 10.52 (5.93 to 17.98) 93.05 
Non-hospitalised n = 3   61/981  5.95 (1.53 to 20.50) 56.24 
Excessive sputum/ 
Expectoration 
Hospitalised n = 5   97/1498  6.02 (3.20 to 11.03) 82.16 
0.112 
Non-hospitalised n = 1   16/451  3.55 (2.18 to 5.71) NA 
Other cardiovascular 
symptoms 
Hospitalised n = 2   78/1185  4.20 (0.00 to 99.97) 97.68 
0.009 
Mixed n = 1    1/767  0.13 (0.02 to 0.92) NA 
Palpitations 
Mixed n = 2   53/1146  4.67 (0.60 to 28.47) 62.05 
<0.001 Hospitalised n = 6  416/3536 12.43 (7.78 to 19.29) 91.7 
Non-hospitalised n = 1    7/ 96  7.29 (3.52 to 14.51) NA 
Gastrointestinal 
Diarrhoea 
Hospitalised n = 7  138/2809  2.93 (0.90 to 9.12) 81.91 
0.077 Non-hospitalised n = 3   40/981  4.16 (0.72 to 20.65) 84.27 
Mixed n = 1   12/135  8.89 (5.12 to 15.00) NA 
Nausea or Vomiting 
Hospitalised n = 2   21/139  5.84 (0.00 to 100.00) 0 
0.343 Non-hospitalised n = 2   16/547  3.66 (0.00 to 98.24) 89.91 
Mixed n = 1   12/135  8.89 (5.12 to 15.00) NA 
Stomach/ Abdominal pain 
Hospitalised n = 2   10/209  4.63 (0.03 to 89.20) 54.79 
0.002 Non-hospitalised n = 1   15/451  3.33 (2.01 to 5.44) NA 
Mixed n = 1    5/767  0.65 (0.27 to 1.56) NA 
Weight loss 
Non-hospitalised n = 1   47/434 10.83 (8.23 to 14.12) NA 
<0.001 
Hospitalised n = 1   50/134 37.31 (29.55 to 45.79) NA 
Musculoskeletal Impaired mobility 
Hospitalised n = 5  316/2731 17.33 (4.75 to 46.83) 98.49 
0.038 
Mixed n = 1    7/135  5.19 (2.49 to 10.48) NA 
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Joint pain/ Arthralgia 
Hospitalised n = 8  395/3509  9.36 (5.25 to 16.14) 94.81 
0.987 
Non-hospitalised n = 1   42/451  9.31 (6.95 to 12.36) NA 
Muscle pain/ Myalgia 
Mixed n = 4  128/1416 10.86 (3.45 to 29.36) 95.21 
0.954 Hospitalised n = 7  199/2819 12.46 (4.30 to 31.09) 98.05 
Non-hospitalised n = 2   51/547 10.76 (0.24 to 85.64) 85.87 
Neurocognitive 
Confusion 
Non-hospitalised n = 1   10/451  2.22 (1.20 to 4.07) NA 
0.419 
Mixed n = 1   23/767  3.00 (2.00 to 4.47) NA 
Memory impairment 
Mixed n = 2   40/514  8.06 (0.00 to 99.97) 97.38 
<0.001 Hospitalised n = 3   96/276 34.78 (23.64 to 47.88) 0 
Non-hospitalised n = 1   15/ 96 15.62 (9.64 to 24.32) NA 
Other cognitive impairment 
Mixed n = 2  109/307 23.55 (0.00 to 100.00) 98.87 
0.581 
Hospitalised n = 1   13/134  9.70 (5.72 to 15.99) NA 
Neurological and 
neuromuscular 
Decreased sensation or 
sensibility 
Mixed n = 1   20/135 14.81 (9.76 to 21.85) NA 
0.060 
Hospitalised n = 1   10/134  7.46 (4.06 to 13.31) NA 
Headache 
Mixed n = 3   40/1281  3.30 (0.12 to 50.20) 93.93 
0.145 Hospitalised n = 5   71/2093  2.98 (0.47 to 16.53) 96.56 
Non-hospitalised n = 4  116/1161  8.82 (4.41 to 16.85) 86.25 
Smell disturbance 
Mixed n = 6  210/1744 14.63 (5.46 to 33.72) 97.32 
0.108 Hospitalised n = 9  308/2660 12.16 (7.98 to 18.10) 85.48 
Non-hospitalised n = 5  324/1264 22.19 (11.69 to 38.04) 96.3 
Taste disturbance 
Mixed n = 5  197/1609 14.50 (3.40 to 44.98) 98.32 
0.425 Hospitalised n = 8  232/2550 11.07 (6.90 to 17.28) 89.1 
Non-hospitalised n = 5  258/1264 16.83 (7.91 to 32.26) 95.66 
Tingling/ Paraesthesia 
Hospitalised n = 1    4/122  3.28 (1.24 to 8.41) NA 
<0.001 
Mixed n = 1   29/135 21.48 (15.36 to 29.21) NA 
Tremors 
Mixed n = 1   13/135  9.63 (5.67 to 15.88) NA 
<0.001 Non-hospitalised n = 1    4/451  0.89 (0.33 to 2.34) NA 
Hospitalised n = 1   25/538  4.65 (3.16 to 6.79) NA 
Visual disturbance 
Mixed n = 1    9/135  6.67 (3.50 to 12.32) NA 
0.245 
Non-hospitalised n = 1   19/451  4.21 (2.70 to 6.51) NA 
Walking/ Gait abnormality 
Hospitalised n = 2   27/674  4.01 (0.34 to 33.61) 0 
0.534 
Mixed n = 1    7/135  5.19 (2.49 to 10.48) NA 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health





Mixed n = 1   12/379  3.17 (1.81 to 5.49) NA 
<0.001 Hospitalised n = 4  541/2335 23.54 (17.68 to 30.61) 74.84 
Non-hospitalised n = 1   10/ 96 10.42 (5.70 to 18.29) NA 
Skin rash 
Hospitalised n = 3   60/1923  3.53 (0.75 to 15.11) 82.97 
0.112 
Non-hospitalised n = 1    7/451  1.55 (0.74 to 3.22) NA 
Psychological and social 
Anxiety 
Hospitalised n = 4  524/2423 25.58 (6.36 to 63.49) 97.85 
0.072 
Mixed n = 3  126/1128 11.60 (6.03 to 21.15) 72 
Care dependency 
Hospitalised n = 1   25/1611  1.55 (1.05 to 2.29) NA 
<0.001 
Mixed n = 2  135/944 12.00 (0.39 to 82.45) 85.63 
Depression 
Mixed n = 4   95/1507  6.80 (3.99 to 11.37) 71 
0.506 
Hospitalised n = 2  390/2155 10.38 (0.00 to 99.83) 98.62 
Low mood/ Dysphoria 
Mixed n = 1    0/226  0.00 (0.00 to 100.00) NA 
1.000 
Hospitalised n = 2   62/672  9.49 (0.00 to 100.00) 98.92 
PTSD 
Hospitalised n = 3   59/474 10.52 (3.06 to 30.44) 80.04 
0.458 Non-hospitalised n = 1   32/455  7.03 (5.02 to 9.78) NA 
Mixed n = 3  238/1128  8.73 (0.46 to 66.23) 96.63 
Reduced quality of life 
Mixed n = 2   81/267 30.34 (7.43 to 70.27) 0 
<0.001 
Hospitalised n = 1  259/540 47.96 (43.77 to 52.18) NA 
Sleep disorder 
Mixed n = 4  100/885 10.66 (1.76 to 44.22) 96.51 
0.081 
Hospitalised n = 5  642/2557 25.81 (18.85 to 34.26) 84.7 
Systemic 
Dizziness 
Mixed n = 2   18/514  3.78 (0.03 to 83.74) 79.93 
0.224 Non-hospitalised n = 1   29/434  6.68 (4.68 to 9.45) NA 
Hospitalised n = 2  115/2193  4.21 (0.08 to 71.53) 89.39 
Fatigue 
Hospitalised n = 11 1762/4147 37.10 (26.54 to 49.06) 98.23 
0.017 Non-hospitalised n = 4  200/813 24.60 (20.11 to 29.72) 0 
Mixed n = 3  245/1079 21.04 (10.48 to 37.75) 79.86 
Fever 
Hospitalised n = 4   17/1876  0.85 (0.02 to 24.20) 92.05 
0.661 Non-hospitalised n = 3   25/981  1.41 (0.06 to 24.82) 84.73 
Mixed n = 1    5/767  0.65 (0.27 to 1.56) NA 
Sweat or night sweats 
Mixed n = 1   35/145 24.14 (17.87 to 31.76) NA 
0.894 
Hospitalised n = 1  127/538 23.61 (20.21 to 27.38) NA 
Weakness Mixed n = 1  113/379 29.82 (25.42 to 34.61) NA <0.001 
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Hospitalised n = 1   73/134 54.48 (46.00 to 62.70) NA 
Upper respiratory 
Nasal congestion 
Non-hospitalised n = 3   49/981  4.99 (2.72 to 8.99) 0 
0.924 
Hospitalised n = 1    1/ 22  4.55 (0.64 to 26.15) NA 
Other respiratory symptoms 
Hospitalised n = 2  240/660 32.43 (2.22 to 91.02) 88.57 
<0.001 
Non-hospitalised n = 1   13/451  2.88 (1.68 to 4.90) NA 
Sore throat 
Hospitalised n = 4  103/2349  4.81 (1.60 to 13.60) 85.83 
0.815 
Non-hospitalised n = 2   24/547  4.39 (0.32 to 39.44) 0 
 
  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health
 doi: 10.1136/bmjgh-2021-005427:e005427. 6 2021;BMJ Global Health, et al. Michelen M
28 
 
Supplement 6: Subgroup analysis: Setting 
Classification Symptom Subgroup N Studies Event/total Proportion% (95% CIs) Heterogeneity (%) P value 
Cardiopulmonary 
Cough 
Multicentre n = 5 121/1358 6.90 (2.46 to 17.92) 84.05 
0.842 Single-centre n = 10 260/3239 9.07 (4.23 to 18.41) 95.62 
Online survey n = 1 33/ 434 7.60 (5.46 to 10.50) NA 
Chest pain 
Single-centre n = 10 292/4760 5.87 (2.70 to 12.26) 93.7 
0.039 
Multicentre n = 1 16/ 118 13.56 (8.48 to 20.99) NA 
Breathlessness/ Exertional 
dyspnoea 
Multicentre n = 6 350/1437 26.79 (15.81 to 41.63) 91.82 
<0.001 Single-centre n = 12 889/3549 27.78 (17.16 to 41.67) 96.93 
Online survey n = 2 58/ 537 10.80 (2.03 to 41.47) 16.75 
Palpitations 
Single-centre n = 6 359/4120 9.02 (5.17 to 15.27) 90.72 
0.571 
Multicentre n = 2 117/ 658 11.96 (0.02 to 98.84) 91.67 
Excessive sputum/ 
Expectoration 
Multicentre n = 3 81/1105 6.97 (2.02 to 21.38) 86.45 
0.066 
Single-centre n = 3 32/ 844 3.79 (1.78 to 7.88) 24.53 
Gastrointestinal 
Weight loss 
Online survey n = 1 47/ 434 10.83 (8.23 to 14.12) NA 
<0.001 
Single-centre n = 1 50/ 134 37.31 (29.55 to 45.79) NA 
Stomach/ Abdominal pain 
Single-centre n = 2 7/ 859 0.81 (0.01 to 50.51) 52.12 
<0.001 
Multicentre n = 2 23/ 568 4.05 (0.28 to 38.69) 64.62 
Loss of appetite 
Single-centre n = 2 174/1789 15.09 (0.03 to 98.93) 97.64 
0.288 
Multicentre n = 1 28/ 117 23.93 (17.06 to 32.48) NA 
Diarrhoea 
Single-centre n = 4 85/2130 1.81 (0.36 to 8.72) 72.7 
0.081 Multicentre n = 5 80/1361 6.23 (2.49 to 14.76) 85.33 
Online survey n = 1 25/ 434 5.76 (3.92 to 8.39) NA 
Musculoskeletal 
Impaired mobility 
Single-centre n = 4 294/2191 23.71 (6.53 to 58.01) 98.62 
<0.001 
Multicentre n = 2 29/ 675 4.30 (0.40 to 33.37) 0 
Joint pain/ Arthralgia 
Single-centre n = 7 264/2969 8.03 (4.64 to 13.55) 86.94 
0.116 
Multicentre n = 2 173/ 991 15.45 (0.11 to 96.89) 97.19 
Muscle pain/ Myalgia 
Multicentre n = 4 103/ 839 13.72 (6.26 to 27.48) 89.49 
0.508 




Single-centre n = 2 118/ 264 40.19 (0.00 to 100.00) 99 
0.017 
Multicentre n = 1 4/ 177 2.26 (0.85 to 5.86) NA 
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Multicentre n = 1 10/ 451 2.22 (1.20 to 4.07) NA 
0.419 
Single-centre n = 1 23/ 767 3.00 (2.00 to 4.47) NA 
Memory impairment 
Multicentre n = 2 50/ 253 19.76 (3.21 to 64.68) 8.97 
0.821 
Single-centre n = 3 101/ 633 16.93 (0.58 to 87.62) 97.39 
Neurological and 
neuromuscular 
Walking/ Gait abnormality 
Multicentre n = 2 29/ 675 4.30 (0.40 to 33.37) 0 
0.766 
Single-centre n = 1 5/ 134 3.73 (1.56 to 8.65) NA 
Tremors 
Multicentre n = 2 17/ 586 2.98 (0.00 to 99.96) 94.5 
0.615 
Single-centre n = 1 25/ 538 4.65 (3.16 to 6.79) NA 
Headache 
Single-centre n = 6 95/3217 2.82 (0.69 to 10.88) 96.4 
<0.001 Multicentre n = 4 65/ 884 7.35 (5.00 to 10.68) 37.26 
Online survey n = 1 67/ 434 15.44 (12.34 to 19.15) NA 
Smell disturbance 
Multicentre n = 6 197/1196 17.21 (13.03 to 22.38) 68.78 
0.235 Single-centre n = 11 443/3935 12.49 (7.13 to 20.97) 95.97 
Online survey n = 2 202/ 537 27.06 (0.04 to 99.70) 96.07 
Taste disturbance 
Single-centre n = 10 383/3825 12.21 (6.16 to 22.76) 97.3 
0.793 Multicentre n = 5 143/1061 14.27 (10.13 to 19.73) 65.8 
Online survey n = 2 161/ 537 18.21 (0.00 to 99.91) 95.82 
Tingling/ Paraesthesia 
Single-centre n = 1 4/ 122 3.28 (1.24 to 8.41) NA 
<0.001 
Multicentre n = 1 29/ 135 21.48 (15.36 to 29.21) NA 
Decreased sensation or 
sensibility 
Multicentre n = 1 20/ 135 14.81 (9.76 to 21.85) NA 
0.060 
Single-centre n = 1 10/ 134 7.46 (4.06 to 13.31) NA 
Other 
Hair loss 
Multicentre n = 1 14/ 118 11.86 (7.15 to 19.04) NA 
0.630 
Single-centre n = 4 549/2692 14.99 (3.66 to 45.01) 95.58 
Skin rash 
Single-centre n = 3 60/1923 3.53 (0.75 to 15.11) 82.97 
0.112 
Multicentre n = 1 7/ 451 1.55 (0.74 to 3.22) NA 
Psychological and social 
Care dependency 
Single-centre n = 2 146/2378 5.16 (0.00 to 99.97) 99.18 
0.621 
Multicentre n = 1 14/ 177 7.91 (4.74 to 12.91) NA 
PTSD 
Multicentre n = 2 54/ 706 7.65 (1.35 to 33.36) 0 
0.653 
Single-centre n = 4 275/1351 9.73 (1.74 to 39.56) 95.56 
Sleep disorder 
Single-centre n = 7 665/3162 15.96 (6.78 to 33.15) 95.15 
0.119 
Multicentre n = 2 77/ 280 27.41 (2.84 to 82.98) 77.28 
Depression Single-centre n = 5 474/3527 8.06 (3.47 to 17.62) 97.89 0.979 
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Multicentre n = 1 11/ 135 8.15 (4.57 to 14.11) NA 
Anxiety 
Single-centre n = 6 626/3416 18.92 (7.55 to 40.00) 97.66 
0.870 
Multicentre n = 1 24/ 135 17.78 (12.21 to 25.16) NA 
Systemic 
Dizziness 
Single-centre n = 3 124/2572 3.55 (1.05 to 11.30) 87.17 
0.138 Online survey n = 1 29/ 434 6.68 (4.68 to 9.45) NA 
Multicentre n = 1 9/ 135 6.67 (3.50 to 12.32) NA 
Sweat or night sweats 
Multicentre n = 1 35/ 145 24.14 (17.87 to 31.76) NA 
0.894 
Single-centre n = 1 127/ 538 23.61 (20.21 to 27.38) NA 
Fever 
Single-centre n = 4 22/2621 0.98 (0.06 to 14.94) 94.58 
<0.001 Online survey n = 1 22/ 434 5.07 (3.36 to 7.58) NA 
Multicentre n = 2 3/ 569 0.53 (0.00 to 89.24) 0 
Fatigue 
Single-centre n = 10 1781/4352 36.55 (25.00 to 49.88) 98.57 
0.067 Multicentre n = 5 297/1150 24.28 (17.14 to 33.19) 78.24 




Single-centre n = 2 240/ 660 32.43 (2.22 to 91.02) 88.57 
<0.001 
Multicentre n = 1 13/ 451 2.88 (1.68 to 4.90) NA 
Nasal congestion 
Online survey n = 1 23/ 434 5.30 (3.55 to 7.85) NA 
0.690 
Multicentre n = 2 27/ 569 4.75 (0.41 to 37.90) 25.27 
Sore throat 
Single-centre n = 3 103/2327 5.38 (1.20 to 20.94) 90.55 
0.538 
Multicentre n = 2 24/ 569 4.22 (0.31 to 38.40) 0.31 
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Supplement 7: Subgroup analysis: Continents 
Classification Symptom Subgroup N Studies Event/total Proportion% (95% CIs) Heterogeneity (%) P value 
Cardiopulmonary 
Cough 
Europe n = 11 267/3074 9.71 (4.88 to 18.39) 94.92 
0.057 Asia n = 4 146/1839 7.64 (4.60 to 12.44) 79.54 
North America n = 1 1/ 118 0.85 (0.12 to 5.77) NA 
Chest pain 
Asia n = 3 157/2840 4.11 (0.23 to 44.11) 97.52 
0.097 Europe n = 7 135/1920 6.93 (2.77 to 16.31) 89.56 
North America n = 1 16/ 118 13.56 (8.48 to 20.99) NA 
Breathlessness/ Exertional 
dyspnoea 
Europe n = 13 868/3336 28.59 (18.52 to 41.35) 96.32 
0.227 
Asia n = 4 328/1839 16.53 (7.91 to 31.34) 95.25 
Middle East n = 2 70/ 230 22.35 (0.00 to 99.99) 97.16 
North America n = 1 31/ 118 26.27 (19.13 to 34.93) NA 
Other cardiovascular 
symptoms 
Europe n = 1 1/ 767 0.13 (0.02 to 0.92) NA 
0.009 
Asia n = 2 78/1185 4.20 (0.00 to 99.97) 97.68 
Palpitations 
Asia n = 4 387/3380 12.04 (7.03 to 19.85) 93.93 
0.168 Europe n = 3 82/1280 8.10 (1.14 to 40.21) 95.9 
North America n = 1 7/ 118 5.93 (2.85 to 11.92) NA 
Excessive sputum/ 
Expectoration 
Asia n = 3 81/1192 6.56 (1.54 to 23.96) 90.08 
0.238 
Europe n = 3 32/ 757 4.23 (1.99 to 8.76) 0 
Gastrointestinal 
Stomach/ Abdominal pain 
Europe n = 3 22/1310 1.61 (0.22 to 10.84) 80.31 
0.011 
Asia n = 1 8/ 117 6.84 (3.46 to 13.08) NA 
Loss of appetite 
Asia n = 2 166/1772 13.98 (0.06 to 97.66) 96.44 
0.088 
Europe n = 1 36/ 134 26.87 (20.05 to 34.99) NA 
Diarrhoea 
Europe n = 6 49/1495 2.37 (0.80 to 6.77) 80.93 
0.055 Asia n = 3 133/2312 7.38 (2.34 to 20.91) 89.09 
North America n = 1 8/ 118 6.78 (3.43 to 12.97) NA 
Nausea or Vomiting 
Europe n = 2 20/ 586 3.92 (0.00 to 98.84) 92.31 
0.004 Asia n = 1 21/ 117 17.95 (12.00 to 25.97) NA 
North America n = 1 8/ 118 6.78 (3.43 to 12.97) NA 
Musculoskeletal Impaired mobility 
Asia n = 2 135/2162 5.63 (0.46 to 43.57) 82.31 
<0.001 
Europe n = 3 126/ 577 16.90 (2.10 to 65.88) 92.96 
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Middle East n = 1 62/ 127 48.82 (40.25 to 57.46) NA 
Joint pain/ Arthralgia 
Asia n = 3 326/2733 12.25 (3.07 to 38.13) 97.8 
0.295 
Europe n = 6 111/1227 8.03 (4.01 to 15.42) 88.36 
Muscle pain/ Myalgia 
Europe n = 9 294/2471 14.02 (7.27 to 25.34) 96.38 
<0.001 Asia n = 2 63/2193 3.11 (0.16 to 38.54) 83.96 




Europe n = 2 118/ 264 40.19 (0.00 to 100.00) 99 
0.017 
North America n = 1 4/ 177 2.26 (0.85 to 5.86) NA 
Memory impairment 
North America n = 1 20/ 118 16.95 (11.20 to 24.82) NA 
0.898 
Europe n = 4 131/ 768 18.19 (3.02 to 61.38) 96.14 
Neurological and 
neuromuscular  
Walking/ Gait abnormality 
Europe n = 2 12/ 269 4.46 (0.11 to 66.56) 0 
0.796 
Asia n = 1 22/ 540 4.07 (2.70 to 6.11) NA 
Tremors 
Europe n = 2 17/ 586 2.98 (0.00 to 99.96) 94.5 
0.615 
Asia n = 1 25/ 538 4.65 (3.16 to 6.79) NA 
Headache 
Asia n = 1 33/1655 1.99 (1.42 to 2.79) NA 
0.005 Europe n = 9 187/2762 5.30 (2.12 to 12.66) 92.94 
North America n = 1 7/ 118 5.93 (2.85 to 11.92) NA 
Smell disturbance 
Europe n = 15 602/3615 15.35 (9.88 to 23.06) 96.43 
0.027 
Asia n = 1 176/1655 10.63 (9.24 to 12.21) NA 
North America n = 2 49/ 295 16.74 (1.75 to 69.42) 65.9 
Middle East n = 1 15/ 103 14.56 (8.97 to 22.76) NA 
Taste disturbance 
Asia n = 1 120/1655 7.25 (6.10 to 8.60) NA 
<0.001 
Europe n = 13 510/3370 14.25 (8.44 to 23.06) 96.81 
North America n = 2 49/ 295 16.74 (1.75 to 69.42) 65.9 
Middle East n = 1 8/ 103 7.77 (3.93 to 14.77) NA 
Other 
Hair loss 
North America n = 1 14/ 118 11.86 (7.15 to 19.04) NA 
0.005 Asia n = 2 513/2193 24.69 (5.86 to 63.32) 90.76 
Europe n = 2 36/ 499 8.21 (0.00 to 99.89) 96.66 
Skin rash 
Asia n = 1 47/1655 2.84 (2.14 to 3.76) NA 
0.952 
Europe n = 3 20/ 719 2.75 (0.30 to 20.89) 86.08 
Psychosological and social Care dependency 
Asia n = 1 25/1611 1.55 (1.05 to 2.29) NA 
<0.001 
North America n = 1 14/ 177 7.91 (4.74 to 12.91) NA 
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Europe n = 1 121/ 767 15.78 (13.36 to 18.53) NA 
Reduced quality of life 
Europe n = 1 28/90 31.11 (22.42 to 41.37) NA 
<0.001 North America n = 1 53/ 177 29.94 (23.66 to 37.09) NA 
Asia n = 1 259/ 540 47.96 (43.77 to 52.18) NA 
Low mood/ Dysphoria 
Europe n = 2 53/ 360 0.86 (0.00 to 100.00) 0 
0.868 
Asia n = 1 9/ 538 1.67 (0.87 to 3.18) NA 
PTSD 
Europe n = 5 322/1937 9.93 (3.21 to 26.84) 96.87 
0.322 
Middle East n = 1 7/ 120 5.83 (2.81 to 11.73) NA 
Sleep disorder 
Asia n = 2 532/2193 22.00 (2.69 to 74.18) 94 
0.486 
Europe n = 7 210/1249 17.09 (7.01 to 36.03) 94.68 
Depression 
Asia n = 2 390/2155 10.38 (0.00 to 99.83) 98.62 
0.506 
Europe n = 4 95/1507 6.80 (3.99 to 11.37) 71 
Anxiety 
Asia n = 2 402/2155 12.63 (0.02 to 98.99) 98.36 
0.320 
Europe n = 5 248/1396 21.85 (8.03 to 47.22) 97.39 
Systemic 
Dizziness 
Asia n = 2 115/2193 4.21 (0.08 to 71.53) 89.39 
0.764 
Europe n = 3 47/ 948 4.76 (1.43 to 14.71) 75.61 
General malaise 
Europe n = 1 25/ 134 18.66 (12.93 to 26.16) NA 
<0.001 
Asia n = 1 267/ 538 49.63 (45.42 to 53.85) NA 
Sweat or night sweats 
Europe n = 1 35/ 145 24.14 (17.87 to 31.76) NA 
0.894 
Asia n = 1 127/ 538 23.61 (20.21 to 27.38) NA 
Fever 
Europe n = 5 44/1851 1.91 (0.36 to 9.62) 90.51 
0.011 Asia n = 1 2/1655 0.12 (0.03 to 0.48) NA 
North America n = 1 1/ 118 0.85 (0.12 to 5.77) NA 
Fatigue 
Europe n = 8 605/2014 34.68 (25.12 to 45.66) 93 
0.382 
North America n = 2 60/ 295 20.71 (0.25 to 96.48) 91.68 
Asia n = 4 1436/3380 31.33 (10.49 to 63.98) 99.42 




Europe n = 2 43/ 573 8.88 (0.00 to 99.98) 97.85 
0.029 
Asia n = 1 210/ 538 39.03 (35.00 to 43.22) NA 
Nasal congestion 
Europe n = 2 42/ 885 4.75 (0.66 to 27.08) 0 
0.343 
North America n = 1 8/ 118 6.78 (3.43 to 12.97) NA 
Sore throat Asia n = 2 86/2193 3.92 (1.00 to 14.17) 8.33 0.165 
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Europe n = 2 38/ 585 7.48 (0.06 to 91.61) 90.13 
North America n = 1 3/ 118 2.54 (0.82 to 7.59) NA 
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Supplement 8: Subgroup analysis: Follow-up timing 
Classification Symptom Subgroup N Studies Event/total Proportion% (95% CIs) Heterogeneity (%) P value 
Cardiopulmonary 
Cough 
< 4 months n = 14 374/4483 8.35 (4.56 to 14.81) 94.34 
0.669 
> 4 months n = 2 40/548 7.30 (0.97 to 38.82) 0 
Chest pain 
> 4 months n = 1 75/1655 4.53 (3.63 to 5.65) NA 
0.311 
< 4 months n = 10 233/3223 6.55 (2.97 to 13.84) 91.52 
Breathlessness/ Exertional 
dyspnoea 
< 4 months n = 15 1142/4562 28.92 (20.29 to 39.41) 96.15 
0.075 
> 4 months n = 5 155/961 15.41 (5.74 to 35.30) 95.81 
Palpitations 
> 4 months n = 1 154/1655 9.31 (8.00 to 10.80) NA 
0.863 
< 4 months n = 7 322/3123 9.71 (5.42 to 16.78) 94.42 
Excessive sputum/ 
Expectoration 
> 4 months n = 1 11/114 9.65 (5.42 to 16.59) NA 
0.069 
< 4 months n = 5 102/1835 4.95 (2.64 to 9.09) 85.74 
Gastrointestinal 
Weight loss 
> 4 months n = 1 47/434 10.83 (8.23 to 14.12) NA 
<0.001 
< 4 months n = 1 50/134 37.31 (29.55 to 45.79) NA 
Loss of appetite 
> 4 months n = 1 138/1655 8.34 (7.10 to 9.77) NA 
<0.001 
< 4 months n = 2 64/251 25.50 (5.15 to 68.31) 0 
Diarrhoea 
< 4 months n = 8 85/1836 3.53 (1.41 to 8.59) 84.4 
0.371 
> 4 months n = 2 105/2089 5.03 (1.46 to 15.89) 0 
Musculoskeletal 
Impaired mobility 
> 4 months n = 3 241/1953 24.29 (2.15 to 82.41) 99.05 
0.108 
< 4 months n = 3 82/913 8.07 (0.95 to 44.49) 96.49 
Joint pain/ Arthralgia 
> 4 months n = 1 154/1655 9.31 (8.00 to 10.80) NA 
0.986 
< 4 months n = 8 283/2305 9.35 (5.22 to 16.17) 94.04 
Muscle pain/ Myalgia 
< 4 months n = 11 339/3127 12.95 (7.31 to 21.91) 96.15 
<0.001 




< 4 months n = 2 118/264 40.19 (0.00 to 100.00) 99 
0.017 




> 4 months n = 3 113/2269 6.11 (0.65 to 39.33) 97.98 
0.620 
< 4 months n = 8 114/2266 4.42 (1.60 to 11.59) 92.68 
Smell disturbance 
< 4 months n = 13 367/2994 13.26 (8.37 to 20.37) 94.8 
0.166 
> 4 months n = 6 475/2674 19.96 (11.27 to 32.87) 97.79 
Taste disturbance > 4 months n = 6 364/2674 15.36 (7.94 to 27.63) 97.61 0.580 
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< 4 months n = 11 323/2749 12.61 (6.95 to 21.81) 96.44 
Other 
Hair loss 
< 4 months n = 4 204/1155 12.72 (3.10 to 39.89) 95.98 
0.181 
> 4 months n = 1 359/1655 21.69 (19.77 to 23.74) NA 
Skin rash 
> 4 months n = 1 47/1655 2.84 (2.14 to 3.76) NA 
0.952 
< 4 months n = 3 20/719 2.75 (0.30 to 20.89) 86.08 
Psychological and social 
Care dependency 
> 4 months n = 2 39/1788 3.38 (0.00 to 98.56) 95.89 
0.006 
< 4 months n = 1 121/767 15.78 (13.36 to 18.53) NA 
Reduced quality of life 
< 4 months n = 2 287/630 40.64 (2.65 to 94.52) 88.36 
0.119 
> 4 months n = 1 53/177 29.94 (23.66 to 37.09) NA 
PTSD 
< 4 months n = 5 322/1937 9.93 (3.21 to 26.84) 96.87 
0.322 
> 4 months n = 1 7/120 5.83 (2.81 to 11.73) NA 
Sleep disorder 
> 4 months n = 1 437/1655 26.40 (24.34 to 28.58) NA 
0.130 
< 4 months n = 8 305/1787 17.20 (8.21 to 32.54) 94.08 
Depression 
> 4 months n = 1 367/1617 22.70 (20.72 to 24.80) NA 
<0.001 
< 4 months n = 5 118/2045 6.16 (3.99 to 9.40) 71.69 
Anxiety 
> 4 months n = 1 367/1617 22.70 (20.72 to 24.80) NA 
0.492 
< 4 months n = 6 283/1934 18.10 (7.16 to 38.77) 97.51 
Systemic 
Dizziness 
> 4 months n = 2 130/2089 6.22 (2.06 to 17.34) 0 
0.011 
< 4 months n = 3 32/1052 3.20 (1.08 to 9.12) 68.78 
Fever 
< 4 months n = 5 23/1535 1.26 (0.22 to 7.01) 90.73 
0.762 
> 4 months n = 2 24/2089 0.79 (0.00 to 100.00) 96.18 
Fatigue 
< 4 months n = 10 890/3243 32.50 (23.93 to 42.42) 94.57 
0.608 
> 4 months n = 7 1317/2796 28.61 (16.00 to 45.73) 98.47 
Upper respiratory 
Nasal congestion 
> 4 months n = 1 23/434 5.30 (3.55 to 7.85) NA 
0.690 
< 4 months n = 2 27/569 4.75 (0.41 to 37.90) 25.27 
Sore throat 
> 4 months n = 1 69/1655 4.17 (3.31 to 5.25) NA 
0.655 
< 4 months n = 4 58/1241 4.84 (1.76 to 12.65) 85.28 
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Supplement 9: Meta-regression: % Female 





20 -0.23 (0.79) -1.93 (1.71) 0.07 0.258 
Chest pain 11 -2.13 (1.85) -1.27 (4.11) 0.01 0.758 
Cough 16 -2.43 (1.12) 0.02 (2.32) 0.00 0.994 
Gastrointestinal Diarrhoea 10 -3.9 (1.46) 1.46 (2.87) 0.00 0.612 




12 -0.37 (1.33) -3.97 (3.05) 0.13 0.194 
Neurological and 
neuromuscular 
Headache 11 -6.29 (1.27) 6.7 (2.46) 0.43 0.007 
Smell disturbance 19 -4.07 (0.53) 4.95 (1.08) 0.56 <0.001 
Taste disturbance 17 -4.29 (0.63) 5.04 (1.27) 0.51 <0.001 
 
 
Figure 13. Metaregression on percentage of female. Neurological and neuromuscular (Headache) 
The bubble plot presents the association between the proportions of females and people experienced headache (p<0.05). Each circle 
represents the value of an individual study, and the size of each circle is proportional to the study weight by inverse-variance weighting. 
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Figure 14. Metaregression on percentage of female. Neurological and neuromuscular (Small disturbance). 
The bubble plot presents the association between the proportions of females and people experienced smell disturbance (p<0.05). Each circle 
represents the value of an individual study, and the size of each circle is proportional to the study weight by inverse-variance weighting. 
 
 
Figure 15. Metaregression on percentage of female. Neurological and neuromuscular (Taste disturbance). 
The bubble plot presents the association between the proportions of females and people experienced taste disturbance (p<0.05). Each circle 
represents the value of an individual study, and the size of each circle is proportional to the study weight by inverse-variance weighting. 
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Supplement 10: Meta-regression: % ICU patients 





14 -1.03 (0.31) 1.02 (0.89) 0.09 0.254 
Cough 11 -2.25 (0.63) -0.75 (2.73) -0.01* 0.783 




11 -2.71 (0.46) 4.19 (2.12) 0.27 0.048 
Neurological and 
neuromuscular 
Smell disturbance 14 -2.24 (0.26) 1.32 (1.3) 0.08 0.311 
Taste disturbance 12 -2.45 (0.25) 1.72 (1.23) 0.16 0.161 
*poor fitting 
 
Figure 16. Metaregression on percentage of ICU patients. Musculoskeletal (Muscle pain/ Myalgia). 
The bubble plot presents the association between the proportions of ICU patients and patients experienced muscle pain/myalgia (p<0.05). 
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Supplement 11: Sensitivity analysis: versus removing high risk of bias studies 
Classification Symptom 
Main results  Main results after removing high risk of bias studies 




n = 3 79/1952 1.38 (0.01 to 67.44) 
 
n = 2 71/1305 1.37 (0.04 to 32.38) 
Palpitations n = 8 476/4778 9.67 (5.95 to 15.34)  n = 7 413/4131 9.65 (5.39 to 16.66) 
Excessive sputum/ 
Expectoration 
n = 6 113/1949 5.46 (3.19 to 9.19) 
 
n = 4 88/1326 6.22 (2.62 to 14.05) 
Cough n = 16 414/5031 8.17 (4.85 to 13.44)  n = 11 265/3207 7.42 (3.38 to 15.55) 
Chest pain n = 11 308/4878 6.36 (3.15 to 12.42)  n = 8 275/3939 7.33 (3.25 to 15.68) 
Breathlessness/ 
Exertional dyspnoea 
n = 20 1297/5523 25.06 (17.86 to 33.97) 
 
n = 14 992/3596 28.85 (19.67 to 40.16) 
Gastrointestinal 
Weight loss n = 2 97/568 20.99 (8.09 to 44.51)  n = 1 50/134 37.31 (29.12 to 46.08) 
Stomach/ Abdominal pain n = 4 30/1427 2.33 (0.54 to 9.42)  n = 2 7/859 0.81 (0.39 to 1.70) 
Loss of appetite n = 3 202/1906 17.49 (4.13 to 51.04)  n = 2 174/1789 15.09 (6.35 to 31.80) 
Diarrhoea n = 10 190/3925 4.00 (2.07 to 7.57)  n = 6 140/2751 4.68 (2.49 to 8.66) 
Nausea or Vomiting n = 4 49/821 6.69 (1.64 to 23.59)  n = 2 20/253 7.91 (5.16 to 11.93) 
Musculoskeletal 
Impaired mobility n = 6 323/2866 14.42 (4.67 to 36.73)  n = 5 257/2662 12.00 (3.02 to 37.39) 
Joint pain/ Arthralgia n = 9 437/3960 9.39 (5.72 to 15.03)  n = 6 378/3215 10.79 (5.21 to 21.00) 




n = 3 122/441 17.77 (0.08 to 98.23) 
 
n = 3 122/441 17.77 (0.08 to 98.23) 
Confusion n = 2 33/1218 2.71 (1.93 to 3.79)  n = 1 23/767 3.00 (1.91 to 4.47) 
Concentration 
impairment 
n = 2 66/254 25.98 (20.96 to 31.73) 
 
n = 1 34/134 25.37 (18.26 to 33.61) 
Memory impairment n = 5 151/886 17.94 (5.26 to 46.25)  n = 4 110/766 14.93 (2.77 to 51.97) 
Neurological and 
neuromuscular 
Tingling/ Paraesthesia n = 2 33/257 9.12 (2.21 to 30.87)  n = 1 29/135 21.48 (14.88 to 29.37) 
Visual disturbance n = 2 28/586 4.78 (3.32 to 6.83)  n = 1 9/135 6.67 (3.09 to 12.28) 
Smell disturbance n = 19 842/5668 15.17 (10.75 to 20.97)  n = 13 513/4258 14.08 (8.87 to 21.62) 
Taste disturbance n = 17 687/5423 13.52 (8.96 to 19.89)  n = 11 425/4013 13.44 (7.31 to 23.42) 
Tremors n = 3 42/1124 3.53 (0.30 to 30.63)  n = 2 38/673 6.20 (3.68 to 10.26) 
Headache n = 11 227/4535 4.88 (2.30 to 10.06)  n = 7 115/3298 4.19 (1.30 to 12.71) 
Other Hair loss n = 5 563/2810 14.34 (5.33 to 33.23)  n = 4 539/2690 13.14 (3.17 to 41.12) 
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Skin rash n = 4 67/2374 2.83 (0.95 to 8.16)  n = 3 60/1923 3.53 (0.75 to 15.11) 
Psychological and 
social 
Sleep disorder n = 9 742/3442 18.15 (9.61 to 31.63) 
 
n = 8 705/3322 16.88 (8.18 to 31.65) 
Systemic 
Dizziness n = 5 162/3141 4.50 (2.53 to 7.86)  n = 4 133/2707 4.02 (1.87 to 8.42) 
Fever n = 7 47/3624 1.08 (0.24 to 4.66)  n = 5 23/2739 0.91 (0.11 to 7.18) 




n = 3 253/1111 15.58 (0.68 to 83.17) 
 
n = 1 210/538 39.03 (34.89 to 43.30) 
Nasal congestion n = 3 50/1003 4.99 (2.73 to 8.92)  n = 1 8/118 6.78 (2.97 to 12.92) 
Sore throat n = 5 127/2896 4.70 (2.42 to 8.91)  n = 4 106/2445 4.70 (1.73 to 12.10) 
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Supplement 12: Sensitivity analysis: versus statistical methods 
Classification Symptom N Studies n/Total 
Main results FTDAT/IV* 




n = 20 1297/5523 25.06 (17.86 to 33.97) 26.68 (20.36 to 33.51) 
Palpitations n = 8 476/4778 9.67 (5.95 to 15.34) 10.21 (6.76 to 14.26) 
Cough n = 16 414/5031 8.17 (4.85 to 13.44) 9.52 (6.16 to 13.50) 
Chest pain n = 11 308/4878 6.36 (3.15 to 12.42) 7.52 (4.29 to 11.52) 
Excessive sputum/ 
Expectoration 
n = 6 113/1949 5.46 (3.19 to 9.19) 5.69 (3.23 to 8.75) 
Flushing n = 1 26/538 4.83 (3.18 to 7.00) 4.83 (3.17 to 6.82) 
Newly diagnosed 
hypertension 
n = 1 7/538 1.30 (0.52 to 2.66) 1.30 (0.49 to 2.46) 
Other cardiovascular 
symptoms 
n = 3 79/1952 1.38 (0.01 to 67.44) 2.99 (0.00 to 12.59) 
Gastrointestinal 
Weight loss n = 2 97/568 20.99 (8.09 to 44.51) 22.47 (3.00 to 52.50) 
Other stomach/ 
Abdominal discomfort 
n = 1 21/117 17.95 (11.47 to 26.12) 17.95 (11.47 to 25.47) 
Loss of appetite n = 3 202/1906 17.49 (4.13 to 51.04) 18.57 (6.35 to 35.21) 
Nausea or Vomiting n = 4 49/821 6.69 (1.64 to 23.59) 7.69 (1.89 to 16.67) 
Diarrhoea n = 10 190/3925 4.00 (2.07 to 7.57) 4.41 (2.65 to 6.57) 
Bloody stools / 
Haematochezia 
n = 1 2/117 1.71 (0.21 to 6.04) 1.71 (0.03 to 5.08) 
Stomach/ Abdominal 
pain 
n = 4 30/1427 2.33 (0.54 to 9.42) 2.63 (0.56 to 5.93) 
Musculoskeletal 
Impaired mobility n = 6 323/2866 14.42 (4.67 to 36.73) 17.09 (7.35 to 29.77) 
Muscle pain/ Myalgia n = 12 378/4782 11.29 (6.17 to 19.75) 13.09 (7.71 to 19.59) 




n = 2 66/254 25.98 (20.96 to 31.73) 25.98 (20.74 to 31.59) 
Memory impairment n = 5 151/886 17.94 (5.26 to 46.25) 20.55 (6.54 to 39.62) 
Other cognitive 
impairment 
n = 3 122/441 17.77 (0.08 to 98.23) 25.51 (0.00 to 79.72) 
Frontal release signs n = 1 20/135 14.81 (9.29 to 21.95) 14.81 (9.27 to 21.35) 
Confusion n = 2 33/1218 2.71 (1.93 to 3.79) 2.69 (1.84 to 3.69) 
Neurological and 
neuromuscular 
Abnormal reflex status n = 1 31/135 22.96 (16.17 to 30.98) 22.96 (16.22 to 30.47) 
Other neurological 
diseases 
n = 1 20/135 14.81 (9.29 to 21.95) 14.81 (9.27 to 21.35) 
Smell disturbance n = 19 842/5668 15.17 (10.75 to 20.97) 16.48 (11.36 to 22.31) 
Taste disturbance n = 17 687/5423 13.52 (8.96 to 19.89) 14.99 (9.76 to 21.09) 
Decreased sensation or 
sensibility 
n = 2 30/269 10.90 (6.71 to 17.22) 10.88 (4.73 to 19.05) 
Tingling/ Paraesthesia n = 2 33/257 9.12 (2.21 to 30.87) 10.74 (0.02 to 34.12) 
Muscle atrophy n = 1 9/135 6.67 (3.09 to 12.28) 6.67 (2.98 to 11.58) 




n = 1 7/135 5.19 (2.11 to 10.39) 5.19 (1.98 to 9.67) 
Visual disturbance n = 2 28/586 4.78 (3.32 to 6.83) 4.86 (2.79 to 7.43) 
Abnormal muscle tone n = 1 6/135 4.44 (1.65 to 9.42) 4.44 (1.50 to 8.68) 
Tremors n = 3 42/1124 3.53 (0.30 to 30.63) 4.12 (0.76 to 9.75) 
Walking/ Gait 
abnormality 
n = 3 34/809 4.20 (2.02 to 8.53) 4.11 (2.80 to 5.63) 
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Trigeminal neuralgia n = 1 4/122 3.28 (0.90 to 8.18) 3.28 (0.71 to 7.33) 
Speech difficulty/ 
Dysarthria 
n = 1 3/135 2.22 (0.46 to 6.36) 222 (0.28 to 5.56) 
Ear/ Hearing 
conditions 
n = 1 5/451 1.11 (0.36 to 2.57) 1.11 (0.31 to 2.33) 
Lack of coordination/ 
Dysmetria 
n = 1 2/135 1.48 (0.18 to 5.25) 1.48 (0.02 to 4.41) 
Seizures/ Cramps n = 1 6/451 1.33 (0.49 to 2.87) 1.33 (0.44 to 2.63) 
Other 
Hair loss n = 5 563/2810 14.34 (5.33 to 33.23) 15.86 (7.42 to 26.68) 
Skin rash n = 4 67/2374 2.83 (0.95 to 8.16) 2.86 (1.29 to 4.96) 
Conjunctivitis n = 1 8/451 1.77 (0.77 to 3.47) 1.77 (0.73 to 3.23) 
Psychological and 
social 
Reduced quality of life n = 3 340/807 36.76 (18.43 to 59.93) 36.60 (23.89 to 50.32) 
Anxiety n = 7 650/3551 18.73 (8.89 to 35.25) 20.39 (11.95 to 30.38) 
Sleep disorder n = 9 742/3442 18.15 (9.61 to 31.63) 20.01 (12.32 to 28.99) 
PTSD n = 6 329/2057 9.14 (3.66 to 21.04) 10.41 (3.36 to 20.59) 
Depression n = 6 485/3662 8.06 (4.14 to 15.10) 8.72 (3.02 to 16.93) 
Care dependency n = 3 160/2555 5.89 (0.46 to 45.96) 7.24 (0.36 to 21.24) 
Low mood/ Dysphoria n = 3 62/898 1.79 (0.00 to 98.74) 7.49 (0.00 to 31.80) 
Systemic 
Weakness n = 2 186/513 41.20 (25.43 to 59.01) 41.62 (19.16 to 66.08) 
General malaise n = 2 292/672 32.68 (14.91 to 57.36) 33.47 (8.11 to 65.59) 
Fatigue n = 17 2207/6039 30.97 (23.91 to 39.03) 31.75 (22.81 to 41.41) 
Sweat or night sweats n = 2 162/683 23.72 (20.68 to 27.05) 23.68 (20.55 to 26.96) 
Dizziness n = 5 162/3141 4.50 (2.53 to 7.86) 4.58 (2.80 to 6.76) 
Enlarged lymph nodes/ 
Lymphadenopathy 
n = 1 4/451 0.89 (0.24 to 2.26) 0.89 (0.19 to 2.01) 




n = 3 253/1111 15.58 (0.68 to 83.17) 19.30 (0.95 to 52.06) 
Voice change n = 1 11/134 8.21 (4.17 to 14.21) 8.21 (4.08 to 13.53) 
Nasal congestion n = 3 50/1003 4.99 (2.73 to 8.92) 4.89 (3.61 to 6.34) 
Sore throat n = 5 127/2896 4.70 (2.42 to 8.91) 4.66 (2.94 to 6.74) 
* FTDAT/IV: Freeman-Tukey Double arcsine transformation within inverse Variance Method 
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Supplement 13: Funnel plots 
The following funnel plots present the proportion of people experienced with certain symptoms against the standard errors (Egger’s method) 
or sample size (Peter’s method) to assess potential publication bias and small study effects. Only symptoms reported 10 or more are presented 
here.  
 
Figure 17. Funnel plot. Cardiopulmonary (Breathlessness or Exertional dyspnoea) by Egger's method 
 
 
Figure 18. Funnel plot. Cardiopulmonary (Breathlessness or Exertional dyspnoea) by Peter's method 
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Figure 19. Funnel plot. Cardiopulmonary (Chest pain) by Egger's method 
 
 
Figure 20. Funnel plot. Cardiopulmonary (Chest pain) by Peter's method 
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Figure 22. Funnel plot. Cardiopulmonary (Cough) by Peter's method 
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Figure 24. Funnel plot. Gastrointestinal (Diarrhoea) by Peter's method 
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Figure 26.  Funnel plot. Musculoskeletal (Muscle pain or Myalgia) by Peter's method 
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Figure 28. Neurological and neuromuscular (Headache) by Peter's method 
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Figure 30. Neurological and neuromuscular (Smell disturbance) by Peter's method 
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Figure 32. Funnel plot. Neurological and neuromuscular (Taste disturbance) by Peter's method 
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Figure 34. Funnel plot. Systemic (Fatigue) by Peter's method 
 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health
 doi: 10.1136/bmjgh-2021-005427:e005427. 6 2021;BMJ Global Health, et al. Michelen M
54 
 
Supplement 14: Risk factors 
Study Category Risk factor Associated with Method P Value/ CI 
Nguyen et al. Sex Female sex Persistent symptoms 
Chi-squared or the 
Fisher exact test 
p = 0.02 
Mazza et al. 
Sex Female sex 




(Wilks’ λ = 0.92; F = 5.76; p = 0.003) 
Comorbidities Previous psychiatric diagnosis  (Wilks’ λ = 0.93; F = 5.29; p = 0.006) 
Severity 
Presence of psychopathology 
at one-month 
(Wilks’ λ = 0.82; F = 15.16; p < 0.001) 
Parentes-Arias 
et al. 




p = 0.028 
Sex Female sex p = 0.003 
Comorbidities 1 comorbidity p = 0.031 
Xiong et al. 
Sex Female sex Covid-19 sequelae 
Multivariable logistic 
regression model 
Physical decline/fatigue (p < 0.01)  
Postactivity polypnoea (p= 0.04)  





postactivity polypnoea and 
resting heart rate increases 
Univariate analysis 
Physical decline/fatigue (p=.02) 
Postactivity polypnoea (p=.01) 
Resting heart rate increases (p=.01) 
Sykes et al. Sex Female sex Persistent symptoms 
Chi-Square and Mann–
Whitney U testing 
Anxiety (p=0.001),low mood (p=0.031), 
myalgia (p=0.022), fatigue (p=0.004), sleep 
disturbance (p=0.009), and memory 
impairment (p=0.001) 
Taboada et al. 
Age Age 
Limitations in the 
functional status (grade II-
IV of PCSF) 
Multivariate logistic 
regression model 
(OR = 2.600, 95% CI: 1.192–5.671) 
Severity Length of hospital stay (OR = 1.049, 95% CI: 1.009–1.090) 
Severity  
Admission to ICU / mechanical 
ventilation 
P < 0.001 
Qu et al. 
Sex Female sex 
Poor QoL scores Logistic regression 
(OR: 1.79, 95% CI: 1.04–3.06) 
Age Older age (≥60 years) (OR: 2.44, 95% CI: 1.33–4.47)  
Severity 
Physical symptom after 
discharge 
(OR: 40.15, 95% CI: 9.68–166.49) 
Einvik et al. 





Ethnicity Born outside Norway 
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Severity  Dyspnoea during COVID-19 
Gherlone et al. Comorbidities COPD Dry mouth Multivariable analysis (OR= 9.10, 95% CI: 1.8 -68.49) 
Stavem et al. 
Severity Number of symptoms (10–23) 




(OR= 4.16, 95% CI:2.57 to 6.72, p<0.001) 
Comorbidities ≥2 (OR=2.52, 95%CI: 1.58 to 4.02, p<0.001) 
Baricich et al. 
Severity ICU admission  Physical impairment  
Multivariable logistic 
regression model 
(OR: 3.1, 95%CI: 1.3-7.9, p=0.01) 
Age Age walking ability (SPPB) p  <0.02 
Comorbidities Number or comorbidities 
walking ability (SPPB) 
2MWT  
p  <0.01 
p <0.04 
Sex Male gender SPPB total score p  <0.01 
Jacobson et al. 
Ethnicity Latin ethnicity 
lower expected 6-MWT 
Multivariate analysis 
(-7.40 [-11.55-{-3.25}], p=0.001 
Comorbidities BMI (-0.52 [-0.81-{-0.22}], p=0.001) 
Severity 
Persistence of symptoms at 
follow up 
Shortness of breath P=0.004 
Petersen et al. Age 
Individuals in age group 50-66 




Persistent symptoms Age-stratified analysis 
p=0.003 
p=0.001 
Alharthy et al. Severity  
Increased incidence of 
dyspnoea and fever prior to 
hospital admission, decreased 
ICU admission PaO2/FiO2 
ratio < 100, longer duration of 
mechanical ventilation, 
increased inflammatory 
biomarkers such as lactate 
dehydrogenase, ferritin, and 
D-dimers on ICU admission, 
and significant lung 
abnormalities detected by LUS 
Persistent symptoms 
Continuous variables 
using the Wilcoxon rank 
sum or the student's t-
test. Categorical 
variables were 
examined using the 
Fisher's exact test or 
the Chi square test 
 p < 0.05 
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Severity Pneumonia and ARDS Shortness of breath 
Pearson's correlation 
coefficient and Cox 
regression were used 
Patients who developed ARDS showed higher 
SBP (p=0.05) and DBP (p=0.02) and lower SpO2 
during 6 MWT (p=0.004), FVC (p=0.004) and 
TLC (p<0.001). Patients without ARDS showed 
higher SR (p<0.001), RV (p<0.001), TLC 
(p<0.001) and RV/TLC (p=0.05). 
Han et al. Severity  
Higher baseline CT lung 
involvement score (>=18 out 
of a possible score of 25) 
Fibrotic-like changes in the 
lung at 6 months 
Multivariate analysis (OR: 4.2, 95%CI: 1.2-14) 
Blanco et al. Severity Severity of the disease  
DLCO <80%  and a lower 
serum lactate 
dehydrogenase level  
Multivariate analysis 
DLCO<80% (OR 5.92; 95%CI 2.28–15.37; p < 
0.0001) Serum lactate dehydrogenase (OR 
0.98; 95%CI 0.97–0.99)  
Lerum et al. Severity ICU admission  
Persistent CT 
abnormalities and  
problems in usual activities 
Mann–Whitney U-tests 
or Chi-squared tests 
p=.031 
Bellan et al. 
Severity Higher DLCO 
Decreased risk of physical 
impairment 
Univariate analysis and  
logistic regression 
models 
(OR, 0.96 [95% CI, 0.94-0.98]; P < .001) 
Comorbidities  COPD 
Increase risk of physical 
impairment 




Age, gender, and pre-existing 
diseases such as 
cardiovascular diseases, 
pulmonary diseases, diabetes 
mellitus type 2, and 
malignancy 
Persistence of symptoms, 
patient performance 
status, and CT findings at 
follow-up 
Friedman's or Wilcoxon 
signed-rank test 
p=0.042 to p<0.001 
Mendez et al. 





ICU patients Pulmonary embolism p<0.001 
D-dimer levels Impaired DLCO p= 0.011 
Blanco et al. Severity Lower serum LDH levels Impaired DLCO Multivariate analysis OR 0.98; 95% CI 0.97-0.99; p 0.002 
Qin et al. Severity 
Higher TSS of the chest and 
ARDS lymphocyte count, MPA 




TSS>10.5 (OR: 10.5; 95%CI: 2.5-44.1; P=0.001)  
ARDS ( OR: 4.6; 95%CI: 1.4-15.5; P=0.014 ) 
Long hospital stay  Lung sequelae  
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Rass et al. 




Age Elderly Neurological signs NR NR 
Weng et al. Severity 
Less severe (Lower frequency 
of supplemental oxygen 
therapy (79% vs 94%; 
p=0·016), and lower 






Treated more often with 
proton pump inhibitors (PPIs) 
and corticosteroids and were 




Enteral nutrition (p=0.007) 
Arnold et al.  Severity  Severe cases  Lower physical score 
Mann Whitney-U and 
Kruskal Wallis tests for 
continuous data and 
Fisher’s exact test or 
Chi-squared testing for 
categorical data. 
NR 
Sibila et al. 
Sex Male gender 
Spirometric abnormalities 
3 months after discharge,= 
NR 
Reduced FEV1: (76.9% vs 51.2%, p = 0.005) 
Reduced FVC: (76.3% vs 51.6%, p = 0.008)  
Comorbidities 
Cardiovascular disease  and 
diabetes  
Reduced FEV1: 
Cardiovascular disease (34.2% vs 9.4%, p = 
0.001) 
Diabetes (28.9% vs 12%, p = 0.02) 
Reduced FVC: 
Cardiovascular disease (29.7% vs 11.0%, p = 
0.009) 
Huang et al. 
Severity 
Participants with severity 
scale 5–6  
Higher risk of lung 
diffusion impairment, 
anxiety or depression, and 
fatigue or muscle 
weakness 
Multivariable analysis 
OR 4·60 (95% CI 1·85–11·48) for diffusion 
impairment, OR 1·77 (1·05–2·97) for anxiety or 
depression, and OR 2·69 (1·46–4·96) for 
fatigue or muscle weakness 
Sex Female sex 
ARDS: Acute respiratory distress syndrome; BMI: Body mass index; CT: Computerised Topography; DCLO: diffusing capacity for carbon monoxide; ICU: Intensive care unit; LDH: Lactate dehydrogenase; LUS: 
lung ultrasound; MWT: minute walking test; NR: Not reported; OR: Odds Ratio; PCSF: post covid functional status; QoL: Quality of life; SPPB: Short Physical Performance Battery test; TSS: Toxic shock syndrome 
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